

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 265/18, 413/04, A61K 31/536, A61P 15/00, 35/00		A1	(11) International Publication Number: WO 00/66570
			(43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/11749		(US). ZHI, Lin [CN/US]; 7794 Roan Road, San Diego, CA 92129 (US). JONES, Todd, K. [US/US]; 546 Marview Drive, Solana Beach, CA 92075 (US). MARSCHKE, Keith, B. [US/US]; 12565 Escala Drive, San Diego, CA 92128 (US). TEGLEY, Christopher, M. [US/US]; 478 Thunderhead Street, Thousand Oaks, CA 91360 (US). (74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 1 May 2000 (01.05.00)			
(30) Priority Data: 60/183,013 4 May 1999 (04.05.99) US 09/552,354 19 April 2000 (19.04.00) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/552,354 (CON) Filed on 19 April 2000 (19.04.00)			
(71) Applicants (for all designated States except US): AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07840 (US). LIGAND PHARMACEUTICALS, INC. [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ZHANG, Puwen [CN/US]; 7004 Oriole Court, Audubon, PA 19403 (US). FENSOME, Andrew [GB/US]; 779 Trephanny Lane, Wayne, PA 19087 (US). TEREFEFENKO, Eugene, A. [US/US]; 266 Live Oak Drive, Quakertown, PA 18951			


Published

With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS



(I)



(II)

(57) Abstract

The present invention provides compounds which are agonists of the progesterone receptor and have structures (I) or (II) wherein R₁ and R₂ are independent substituents selected from the group of H, optionally substituted C₁ to C₆ alkyl, alkenyl, alkynyl, or alkynyl groups C₃ to C₈ cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or COR^A or NR^BCOR^A; or R¹ and R² are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; R^A is selected from H, amino, or optionally substituted C₁ to C₃ alkyl, aryl, C₁ to C₃ alkoxy, or C₁ to C₃ aminoalkyl groups; R^B is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl; R³ is H, OH, NH₂, COR^C, or optionally substituted C₁ to C₆ alkyl, C₃ to C₆ alkenyl, or alkynyl groups; R^C is selected from H or optionally substituted C₁ to C₃ alkyl, aryl, C₁ to C₃ alkoxy, or C₁ to C₃ aminoalkyl groups; Q¹ is S, NR⁷; or CR⁸R⁹, R⁵ is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO₂ or NR⁶; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE
RECEPTOR MODULATORS**

Field of the Invention

5

This invention relates to compounds which are agonists of the progesterone receptor, their preparation and utility. This invention also provides methods of using these compounds in the inducement of contraception and the treatment and/or prevention of dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, and prostate.

Background of the Invention

Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, *Science*, **240**, 889, 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR).

The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane *via* passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene.


A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an antagonist.

PR agonists (natural and synthetic) are known to play an important role in the health of women. PR agonists are used in birth control formulations, typically in the presence of an ER agonist, alternatively they may be used in conjunction with a PR

antagonist. ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus which can lead to an increased risk of uterine cancers. Co-administration of a PR agonist reduces/ablates that risk.


The compounds of this invention have been shown to act as competitive
5 inhibitors of progesterone binding to the PR and act as agonists in functional models, either/or *in-vitro* and *in-vivo*. These compounds may be used for contraception, in the treatment of fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and post menopausal hormone replacement therapy.

Jones, *et al* describe in U.S. Patent No. 5,688,810 the PR antagonist
10 dihydroquinoline 1.




1

Jones, *et al*, described the enol ether 2 (U.S. Patent No. 5,693,646) as a PR
15 ligand.



2


Jones, *et al*, described compound 3 (U.S. Patent No. 5,696,127) as a PR ligand.




3

5


Zhi, *et al*, described lactones 4, 5 and 6 as PR antagonists (J. Med. Chem., 41, 291, 1998).



4




5



6

10


Zhi, *et al*, described the ether 7 as a PR antagonist (J. Med. Chem., 41, 291, 1998).



7

Combs, *et al.*, disclosed the amide **8** as a ligand for the PR (*J. Med. Chem.*, **38**, 4880, 1995).


5



8


Perlman, *et al.*, described the vitamin D analog **9** as a PR ligand (*Tet. Letters*, **35**, 2295, 1994).

10




9

Hamann, *et al*, described the PR antagonist **10** (*Ann. N.Y. Acad. Sci.*, **761**, 383, 1995).

**10**


5

Chen, *et al*, described the PR antagonist **11** (Chen, *et al*, POI-37, 16th Int. Cong. Het. Chem., Montana, 1997).

**11**

10


Kurihari, *et. al.*, described the PR ligand **12** (*J. Antibiotics*, **50**, 360, 1997).

**12**

15


Sakata *et al.* (JP 07159917, CA 123:301431) teach that certain benzoxazin-2-thione compounds such as compound **A** can be used as photographic materials. Kim *et al.* disclose that some imidazole substituted benzothiazines, such as compound **B**, can be used as cardiotonics (U.S. Patent No. 5,171,851 and EP 510235). More

recently, Young et al. (WO95/20389) and Christ et al. (WO98/14436) claimed benzoxazin-2-thiones such as compound **C** as inhibitors of HIV reverse transcriptase.



5


Pflegel et al. (Pharmazie, 37(10), 714-717(1982)) disclosed quinazolin-2-thiones such as compound **D** in their study of polarography of heterocyclics, but disclosed no activity for compound **D**.



10

Description of the Invention

This invention provides compounds of the formula:



wherein:

R_1 and R_2 are independent substituents selected from the group of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_2 to C_6 alkenyl, substituted C_2 to C_6 alkenyl, C_2 to C_6 alkynyl, substituted C_2 to C_6 alkynyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , or $NR^B COR^A$;

10

or R^1 and R^2 are fused to form a spirocyclic ring selected from a), b) or c), below, each spirocyclic ring being optionally substituted by from 1 to 3 substituents selected from H or C_1 - C_3 alkyl:

15

- a) a 3 to 8 membered spirocyclic alkyl ring, preferably a 3 to 6 membered spirocyclic alkyl ring; or
- b) a 3 to 8 membered spirocyclic alkenyl ring, preferably a 3 to 6 membered spirocyclic alkenyl ring; or
- 20 c) a 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocyclic ring containing one to three heteroatoms;

R^A is selected from H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, amino, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

25

R^B is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;


R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_1 to C_6 alkenyl, alkynyl, or substituted alkynyl, or COR^C ;

R^C is selected from H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^4 is selected from H, halogen, CN, NO_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, or substituted C_1 to C_6 aminoalkyl;

R^5 is selected from groups a), b), or c) below:

a) R^5 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below:



X is selected from the group including halogen, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkoxy, substituted C_1 to C_3 thioalkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D , $OCOR^D$, or $NR^E COR^D$;

R^D is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independent substituents selected from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkoxy;

or

b) R^5 is a five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, S(O), S(O_2) or NR^6 and containing one


or two independent substituents from the group of H, halogen, CN, NO₂ and C₁ to C₃ alkyl, C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, COR^F, or NR^GCOR^F;

- 5 R^F is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;

R^G is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

R^F is H, or C₁ to C₃ alkyl; or

c) or R^S is a six membered ring with the structure:



10

wherein:

X¹ is N or CX²,

X² is halogen, CN, or NO₂,

Q¹ is S, NR⁷, or CR⁸R⁹;


- 15 R₇ is selected from the group of CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, or substituted heterocyclic, SO₂CF₃, OR¹¹ or NR¹¹R¹²;

R⁸ and R⁹ are independent substituents selected from the group of H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO₂, CN, or CO₂R¹⁰;

20


R¹⁰ is C₁ to C₃ alkyl;

or CR⁸R⁹ comprise a six membered ring as shown by the structure below:



25

Q² is selected from the moieties:




R^{11} , R^{12} and R^{13} are independently selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl;

5 or a pharmaceutically acceptable salt thereof.

A preferred list of substituents represented by R^{11} , R^{12} and R^{13} in groups of the compounds described herein are H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, $-C(O)-$ (C_1 to C_6 alkyl), $-S(O)_2-$ (C_1 to C_6 alkyl), phenyl or benzyl.

Among the preferred compounds of this invention are those of the formula:



10

wherein:

R^1 is H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , or $NR^B COR^A$;

15 R^2 is H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_2 to C_6 alkenyl, substituted C_2 to C_6 alkenyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , or $NR^B COR^A$;

or R^1 and R^2 are fused to form:

20 a) a 3 to 8 membered spirocyclic alkyl ring optionally substituted by from 1 to 3 substituents selected from H or C_1 to C_3 alkyl; or

b) a 3 to 8 membered spirocyclic alkenyl ring optionally substituted by from 1 to 3 substituents selected from H or C_1 to C_3 alkyl; or

c) a 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from the group of O, S and N, the ring being optionally substituted by from 1 to 3 substituents selected from H or C₁ to C₃ alkyl;

5 R^A is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;


 R^B is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

 R³ is H, OH, NH₂, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₆ alkenyl, substituted C₁ to C₆ alkenyl, alkynyl, or substituted alkynyl, or COR^C;

 R^C is H, C₁ to C₄ alkyl, substituted C₁ to C₄ alkyl, aryl, substituted aryl, C₁ to C₄ alkoxy, substituted C₁ to C₄ alkoxy, C₁ to C₄ aminoalkyl, or substituted C₁ to C₄ aminoalkyl;

 R⁴ is H, halogen, CN, NO₂, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₁ to C₆ alkoxy, substituted C₁ to C₆ alkoxy, C₁ to C₆ aminoalkyl, or substituted C₁ to C₆ aminoalkyl;

 R⁵ is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below,



20 X is taken from the group including halogen, CN, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ thioalkoxy, substituted C₁ to C₃ thioalkoxy, C₁ to C₃ aminoalkyl, substituted C₁ to C₃ aminoalkyl, NO₂, C₁ to C₃ perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D, OCOR^D, or NR^ECOR^D;

25 R^D is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independent substituents taken from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkoxy;

or

- 5 R^5 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO_2 or NR^6 and containing one or two independent substituents from the group including H, halogen, CN, NO_2 and C_1 to C_3 alkyl, C_1 to C_3 alkoxy,

R^6 is H, or C_1 to C_3 alkyl,

Q^1 is S, NR^7 , CR^8R^9 ;


- 10 R^7 is selected from CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, SO_2CF_3 , OR^{11} or $NR^{11}R^{12}$;

R^8 and R^9 are independent substituents from the group including H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl,


- 15 aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN or CO_2R^{10} ;

R^{10} is C_1 to C_3 alkyl;

or CR^8R^9 comprise a six membered ring as shown by the structure below



- 20 Q^2 is selected from the moieties:



R^{11} , R^{12} and R^{13} are independently selected from H, C_1 to C_6 alkyl, substituted

- 25 C_1 to C_6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl;

or a pharmaceutically acceptable salt thereof.

Other preferred compounds are those of Formula I wherein:

R^1 and R^2 are independently selected from the group of C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or spirocyclic alkyl constructed by fusing R^1 and R^2 to form


5 a 3 to 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy;

R^4 is H, halogen, NO_2 , C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

10 R^5 is a disubstituted benzene ring containing the substituents X, and Y as shown below:




X is selected from the group of halogen, CN, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C_1 to C_3 thioalkoxy;

15 Y is a substituent selected from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_4 alkyl, or C_1 to C_3 thioalkoxy;

or

R^5 is a five membered ring with the structure shown below :



20 U is O, S, or NR^6 ;


R^6 is H, or C_1 to C_3 alkyl, or C_1 to C_4 CO_2 alkyl;

X' is selected from the group including halogen, CN, NO_2 , C_1 to C_3 alkyl or C_1 to C_3 alkoxy;

Y' is selected from the group of H and C₁ to C₄ alkyl;

or

R⁵ is a six membered ring with the structure:



5 wherein:

X¹ is N or CX²,

X² is halogen, CN, or NO₂,


Q is S, NR⁷, or CR⁸R⁹;

R⁷ is selected from the group of CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl,
 10 C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic,
 substituted heterocyclic, or SO₂CF₃;

R⁸ and R⁹ are independent substituents selected from the group of H, C₁ to C₆
 alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl,
 aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO₂, CN or CO₂R¹⁰;


15 R¹⁰ is C₁ to C₃ alkyl;

CR⁸R⁹ a six membered ring as shown by the structure below



or a pharmaceutically acceptable salts thereof.

20 Further preferred compounds are those of the formula:



wherein:

R^1 and R^2 are independently selected from the group of CH_3 and spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 6 membered spirocyclic ring;


5 R^3 is H, OH, NH_2 , CH_3 , substituted methyl, or COR^C ;

R^C is H, C_1 to C_3 alkyl, or C_1 to C_4 alkoxy;

R^4 is H, halogen, or C_1 to C_3 alkyl;

R^5 is a disubstituted benzene ring containing the substituents X and Y as shown

10 below




X is selected from the group of halogen, CN, methoxy, NO_2 , or 2-thiazole;

Y is a substituent selected from H and F;

or

15 R^5 is a five membered ring with the structure:



U is O, S, or NH;

X is selected from the group of halogen, CN, NO_2 ;

Y is from the group of H and C_1 to C_4 alkyl;


20 Q^1 is selected from S, NR^7 , or CR^8R^9 ;

R^7 is selected from the group of CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^8 and R^9 are independent substituents selected from the group of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN or CO_2R^{10} ;


R^{10} is C_1 to C_3 alkyl;

5 or CR^8R^9 comprise a six membered ring of the structure below:



or a pharmaceutically acceptable salt thereof.

Another preferred subgroup of this invention comprises compounds of the
10 formula:



wherein:

R^1 and R^2 are independently selected from the group of CH_3 and spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 6 membered spirocyclic

15 ring;

R^3 is H, OH, NH_2 , CH_3 , substituted methyl, or COR^C ;


R^C is H, C_1 to C_3 alkyl, or C_1 to C_4 alkoxy;

R^4 is H, halogen, or C_1 to C_3 alkyl;

R^5 is a disubstituted benzene ring containing the substituents X and Y as shown

20 below

- 17 -




X is selected from the group of halogen, CN, methoxy, NO₂, or 2-thiazole;

Y is a substituent selected from H and F;

or

- 5 R⁵ is a five membered ring with the structure:




U is O, S, or NH;

X is selected from the group of halogen, CN, NO₂;

Y is from the group of H and C₁ to C₄ alkyl;

- 10 Q² is selected from the moieties:



R¹¹, R¹² and R¹³ are independently selected from H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl;

- 15 or a pharmaceutically acceptable salt thereof.


20 The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to the stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.

The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having one to eight carbon atoms, preferably one to six carbon atoms; "alkenyl" is intended to include both straight- and branched-chain alkyl group with at least one carbon-carbon double bond and two to eight carbon atoms, preferably one to six carbon atoms; "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least one carbon-carbon triple bond and two to eight carbon atoms, preferably two to six carbon atoms. The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH, NO₂, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio. These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety. The term "aryl" is used herein to refer to an aromatic system which may be a single ring or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system. The aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, phenanthryl. The term "substituted aryl" refers to aryl as just defined having one to four substituents from the group including halogen, CN, OH, NO₂, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio. The term "heterocyclic" is used herein to describe a stable 4- to 7-membered monocyclic or a stable multicyclic heterocyclic ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms. The N and S atoms may be oxidized. The heterocyclic ring also includes any multicyclic ring in which any of above defined heterocyclic rings is fused to an aryl ring. The heterocyclic ring may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable. Such heterocyclic groups include, for example, tetrahydrofuran, piperidinyl, piperazinyl, 2-oxopiperidinyl, azepinyl, pyrrolidinyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, morpholinyl, indolyl, quinolinyl, thienyl, furyl,

benzofuranyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and isoquinolinyl. The term "substituted heterocyclic" is used herein to describe the heterocyclic just defined having one or more substituents selected from the group which includes halogen, CN, OH, NO₂, amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio. The term "alkoxy" is used herein to refer to the OR group, where R is alkyl or substituted alkyl. The term "aryloxy" is used herein to refer to the OR group, where R is aryl or substituted aryl. The term "alkylcarbonyl" is used herein to refer to the RCO group, where R is alkyl or substituted alkyl. The term "alkylcarboxy" is used herein to refer to the COOR group, where R is alkyl or substituted alkyl. The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups, containing one to eight carbon atoms, which may be either same or different and the point of attachment is on the nitrogen atom. The term "halogen" refers to Cl, Br, F, and I elements.

15 The compounds of this invention can be prepared following the Schemes illustrated below:

Scheme 1




As demonstrated in Scheme I, the compounds of this invention are generally prepared by employing the suitable coupling reaction as a final step. An appropriately substituted ortho-amino benzoic acid or its derivatives such as ethyl ester ($X = \text{Br, I, Cl}$, or a latent coupling precursor such as alkoxy group which can be converted into a OTf group suitable in the coupling reaction) was treated with a suitable organo metallic reagent, e.g. Grignard reagent, in appropriate nonprotic solvents which include, but are not limited to, THF or ether to give ortho-amino carbinol 2 under an inert atmosphere such as argon or nitrogen at -78°C to room temperature. Ring

closure of carbinol 2 to yield benzoxazin-2-ones 3 is commonly effected by a condensing agent such as carbonyldiimidazole, phosgene, dimethylcarbonate, or diethylcarbonate in a suitable nonprotic solvent such as THF at temperatures ranging from room temperature to 65 °C. The arylation of benzoxazin-2-ones 3 to yield 4 can be effected by various coupling reactions including Suzuki, Stille reactions. These reactions are commonly performed in the presence of transition metallic catalyst, e.g., palladium or nickel complex often with phosphino ligands, e.g., Ph₃P, dppf, dppe or palladium acetate. Under this catalytic condition, an appropriately substituted nucleophilic reagent, e.g., aryl boronic acid, arylstannane, or aryl zinc compound, is coupled with benzoxazinones 3 to give 4. If a base is needed in the reaction, the commonly used bases include, but are not limited to, sodium bicarbonate, sodium carbonate, potassium phosphate, barium carbonate, or potassium acetate. The most commonly used solvents in these reactions include benzene, DMF, isopropanol, ethanol, DME, ether, acetone, or a mixture of above solvents and water. The coupling reaction is generally executed under an inert atmosphere such as nitrogen or argon at temperatures ranging from room temperature to 95 °C.

Benzoxazinones 3 can be converted into a nucleophile such as boronic acid which can be coupled with an appropriate electrophile, e.g., aryl bromide or aryl iodide, to yield 4 employing the coupling reaction condition as described above. The transformation of 3 into 5 can be effected by treating 3 with an organo metallic reagent, e.g., *n*-BuLi, in a nonprotic solvent such as THF or ether followed by quenching the reaction solution with a suitable electrophile, such as trimethyl borate, triisopropyl borate, or zinc chloride at temperatures ranging from -78 °C to room temperature under an inert atmosphere such as argon or nitrogen.

Scheme 1a



Scheme Ia illustrates an alternative approach leading to the benzoxazinones 3. Thus, an appropriate aniline 1 is protected with a suitable alkoxy carbonyl protective group including but not limited to allenoxycarbonyl, *t*-butoxycarbonyl, benzyloxycarbonyl, ethoxycarbonyl, or methoxycarbonyl in a suitable solvent such as THF, acetonitrile, with or without presence of a base either as a catalyst or as an acid scavenger. The protected aniline is then treated with a suitable organo metallic reagent such as organo lithium agent or Grignard reagent in the same fashion as to prepare compound 2 to give the carbinol 6. The treatment of 2a with a suitable base such as potassium *t*-butoxide, *n*-butyl lithium, potassium hydroxide in an appropriate solvent such as toluene, THF, alcohol under an inert atmosphere such as nitrogen or argon at the temperature ranging from room temperature to the boiling point of the relevant solvent to afford benzoxazinones 3.

Scheme II describes the procedures to prepare benzoxazinones bearing two different substituents at position-4. The Weinreb amide 8 can be prepared from an appropriately substituted isatoic anhydride 7 when treated with *N*-, *O*-dimethylhydroxyl-amine hydrochloride salt in a protic solvent such as ethanol, isopropanol at reflux under an inert atmosphere such as argon or nitrogen. Coupling of amide 8 with an aryl electrophile such as aryl boronic acid or arylstannane to give 9 can be effected by employing a typical coupling reaction such as Suzuki, Stille coupling procedure in a similar fashion as described for the preparation of


benzoxazinones 4. Treatment of Weinreb amide 9 with organo metallic compounds, e.g., alkyllithium, alkynyllithium, aryllithium, or their Grignard counterpart in a nonprotic solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at -78 °C to room temperature affords amino ketone 10. Conversion of

5 ketone 10 to carbinol 11 can be effected by treatment of 10 with an organo metallic reagent such as alkyl, alkynyl, or aryl Grignard compound in a nonprotic solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at -78 °C to room temperature. Conversion of ketone 10 to carbinol 11 can also be effected by

10 reducing reagent such as lithium aluminum hydride, sodium borohydride in a suitable solvent such as THF, ether, or anhydrous alcohol under an inert atmosphere in the temperature range from 0 °C to the boiling point of the solvent. Ring closure of carbinol 11 to produce the compounds of this invention can be accomplished with

15 condensing agents such as carbonyldiimidazole, phosgene, dimethylcarbonate, or diethylcarbonate in a suitable nonprotic solvent such as THF at temperatures ranging from room temperature to 65 °C.


Scheme II



Alternatively, ortho-amino ketone **10** can be prepared by treatment of ortho-amino benzonitrile **14** with an organo metallic compound such as organo lithium reagent or Grignard reagent in a suitable solvent such as THF or ether under an inert

atmosphere such as argon or nitrogen at temperatures ranging from -78 °C to room temperature as illustrated in Scheme III. Benzonitrile **14** can be readily prepared from an appropriately substituted benzonitrile such as bromobenzonitrile **13** using a suitable coupling reaction such as Stille or Suzuki protocol carried out in a similar fashion as described for the preparation of the Weinreb amide **9**.

Scheme III




Scheme IV depicts an approach to prepare benzoxazinones with a low perfluoroalkyl substituent at position-4, e.g. R_6 is trifluoromethyl group. An appropriately substituted chloroaniline **15** was protected with a suitable protective group such as pivaloyl chloride or di-*tert*-butyl pyrocarbonate to give protected aniline **16** in a suitable solvent such as acetonitrile, acetone, THF, methylene chloride, or a mixture of solvent such as methylene chloride and water under an inert atmosphere such as argon or nitrogen at temperatures ranging from 0 °C to 70 °C. A suitable base such as sodium carbonate, sodium bicarbonate, or potassium carbonate may be needed when the reaction

produces an acid as a side-product such as hydrochloride. Treatment of 16 with an appropriate alkyllithium such as *n*-butyllithium or *s*-butyllithium followed by reaction with a low perfluorocarboxy derivatives, e.g., trifluoroacetyl chloride, 1-(trifluoroacetyl)-imidazole, or ethyl trifluoroacetate in a nonprotic solvent such as ether or THF under an inert atmosphere such as argon or nitrogen at -78 °C to ambient temperature gives the protective ortho-amino ketones. Subsequent removal of the protecting group can be effected by reaction of protected amino ketones with a suitable acid such as TFA, 3N aqueous hydrochloride solution in a suitable solvent such as methylene chloride or water at 0 °C to boiling point of the solvent to afford

5 ortho-amino ketone 17.

10


Scheme IV



The preparation of 6-chlorobenzoxazinones 19 from 17 can be accomplished in the same fashion as described for the synthesis of benzoxazinone 12 from ketone 10.

- Coupling of 19 with an aryl group to yield 12 can be effected by a nickel complex catalyzed coupling reaction. The palladium catalysts proved not to be an efficient catalyst in this coupling process. The coupling reaction of 19 with an appropriate aryl boronic acid can be accomplished in the presence of a suitable base such as potassium phosphate and a catalyst of nickel (0 or II) complex, e.g. a nickel complex of 1,2-bis(diphenylphosphino)ethane, 1,1'-bis(diphenylphosphino)ferrocene, or triphenylphosphine. The most commonly used solvents in the reaction include dioxane or THF. The coupling reaction is generally executed under an inert atmosphere such as nitrogen or argon at temperatures ranging from ambient temperature to 95 °C.
- As described in Scheme V the conversion of benzoxazin-2-ones 3 or 12 into benzoxazin-2-thiones 20 or 21 can be accomplished by treatment of 3 or 12 with a suitable sulfur reagent such as Lawesson's reagent in a nonprotic solvent such as o-xylene, chlorobenzene, or toluene under an inert atmosphere such as argon or nitrogen at reflux.

Scheme V



Schemes VI and VII describe the synthesis of other benzoxazinone bioisosteres. Using a similar procedure reported by Kondo et al. (Kondo, et al. *J.*


Med. Chem. 33(7), 2012-2015 (1990)) compound 22 can be formed by treatment of amino carbinol 11 with an appropriate ketene-*S*, *S*-acetals (at least one of R₁₆ or R₁₇ is an electron withdrawing group) in a suitable solvent such as toluene or anhydrous ethanol under an inert atmosphere such as nitrogen or argon at reflux. In a similar

5 fashion, compound 23 can be formed by reaction of amino carbinol 11 with an appropriate imino-*S*, *S*-acetals or imino-acetals (R₁₈ is an electron withdrawing group) employing a procedure similar to that of Evers, et al. (Evers, et al. *I. Prakt. Chem.* 333(5), 699-710 (1991)) or Haake et al. (Haake et al. *Synthesis-Stuttgart* 9, 753-758 (1991)) in a suitable solvent such as ethanol under an inert atmosphere such as argon


10 or nitrogen at reflux. Other procedures (e.g. Wrobel et al. *J. Med. Chem.* 32, 2493(1989)) potentially leading to compounds 22 or 23 from 20 or 21 is illustrated in scheme VIIa. Thus, compound 20 or 21 is alkylated with an appropriate alkylating agent such as the Meerwein reagent in a suitable solvent such as methylene chloride. This is then followed by a nucleophilic replacement of an appropriate nucleophile such

15 as carbon anion or a amine base to give compounds 22 or 23, which may produce either tautomeric form of compounds 22 or 23.


Scheme VI



Scheme VII



Scheme VIIa




As illustrated in Scheme VIII, the compound 21 can be further derivatized at position-1 via numerous approaches leading to a variety of the novel cyclothiocarbamate derivatives including 1-alkyl, substituted 1-alkyl, 1-carbonyl, substituted 1-carbonyl, 1-carboxy, substituted 1-carboxy derivatives. For example, alkyl or substituted alkyl derivatives 24 can be formed by treatment of thiocarbamate 12 or 6 with a suitable base such as sodium hydride in suitable solvent such as DMF under an inert atmosphere, such as argon or nitrogen, followed by addition of an appropriate electrophile such as alkyl or substituted alkyl bromide, iodide, or triflate. Such a transformation of 21 at position-1 can also be effected using a biphasic condition as indicated in Scheme VIII in which alkylation is executed using a biphasic catalyst such as tributylammonium bromide in a suitable solvent such as acetonitrile. A further example of such a modification includes, but is not limited to, heating 21 with triethyl orthoformate to afford 1-substituted derivatives 24. (Scheme VIII)

The acylation or carboxylation of the compound 21 at position-1 to give compound 25 can be readily effected by treatment of 12 or 6 with a suitable acylating or carboxylating reagent such as di-*t*-butyl dicarbonate in the presence of a suitable basic catalyst such as DMAP in a suitable solvent such as acetonitrile under an inert atmosphere such as argon or nitrogen. The amination of position-1 of compound 21

to give compound 26 can be furnished using a suitable aminating reagent such as chloroamine in the presence of a suitable base such as sodium hydride in a suitable solvent such as THF or diethyl ether following the literature procedure (Metlesics et al. *J. Org. Chem.* 30, 1311(1965)).

5

Scheme VIII



The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium,

10

potassium, calcium or magnesium in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety *in vivo*.

5 This invention includes pharmaceutical compositions and treatments which comprise administering to a mammal a pharmaceutically effective amount of one or more compounds as described above as agonists of the progesterone receptor.

10 The progesterone receptor agonists of this invention, used alone or in combination, can be utilized in methods of contraception and the treatment and/or prevention of dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, and prostate. Additional uses of the invention include stimulation of food intake.

15 This invention also includes pharmaceutical compositions utilizing the compounds herein, preferably in combination with a pharmaceutically acceptable carrier or excipient. When the compounds are employed for the above utilities, they may be combined with one or more pharmaceutically acceptable carriers or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more
20 usually between about 5% and 60% by weight.
25

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four
30 times a day, or in a sustained release form. For most large mammals, the total daily

dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For
5 example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include
10 sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example,
15 vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

These active compounds may also be administered parenterally or
20 intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the
25 growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exists. It must be stable under
30 conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can

be a solvent or dispersion medium containing, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.

5 The following examples illustrate preparation of compounds of the invention.

EXAMPLE 1

2-(2-Amino-5-bromophenyl)propan-2-ol

10 A solution of 2-amino-5-bromobenzoic acid (10g, 46 mmol) in dry THF (200 mL) was treated at -78 °C under nitrogen with a solution of methylmagnesium bromide in ether (3.0 M, 90 mL, 270 mmol). The reaction mixture was slowly warmed to ambient temperature, kept stirring for 48 hours under nitrogen and then poured into a cold 0.5 N aqueous hydrochloride solution (300 mL). The mixture was
15 neutralized with aqueous 1 N sodium hydroxide solution and ethyl acetate (300 mL) was added. The organic layer was separated and aqueous layer was extracted with ethyl acetate (3x100 mL). The combined organic layers were washed with brine and dried (MgSO₄). After removal of solvent *in vacuo*, the residue was purified by a silica gel flash chromatography (hexane:ethyl acetate/3:2) to give 2-(2-amino-5-bromophenyl)propan-2-ol as an off-white solid (6g, 57%): mp 62-63 °C; ¹H-NMR (CDCl₃) δ 7.19 (d, 1H, *J* = 2.3 Hz), 7.12 (dd, 1H, *J* = 8.4, 2.3 Hz), 6.51 (d, 1H, *J* = 8.4 Hz), 4.70 (s, 2H), 1.82 (s, 1H), 1.65 (s, 6H).
20

EXAMPLE 2

6-Bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

25 To a solution of 2-(2-amino-5-bromophenyl)propan-2-ol (18g, 78 mmol) in dry THF (150 mL) was added 1,1'-carbonyldiimidazole (15.5g, 94 mmol) under nitrogen. The reaction solution was heated at 50 °C overnight. The solvent was removed *in vacuo* and the residue was dissolved in ethyl acetate (100 mL). The solution was
30 washed with 1N aqueous hydrochloride solution (2x40 mL), brine (20 mL), and dried with MgSO₄. After removal of solvent *in vacuo*, 6-bromo-4,4-dimethyl-1,4-dihydro-

benzo[d][1,3]-oxazin-2-one was obtained as a white solid (20 g, 100%): mp 199-200 °C; ¹H-NMR (DMSO-d₆) δ 10.32 (s, 1H, D₂O exchangeable), 7.48 (d, 1H, *J* = 2.1 Hz), 7.43 (dd, 1H, *J* = 8.5, 2.1 Hz), 6.84 (d, 1H, *J* = 8.4 Hz), 1.61 (s, 6H).

5

EXAMPLE 3**(1,4-Dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid**

To a solution of 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (2g, 7.8 mmol) in anhydrous THF (60 mL) was added a solution of *n*-BuLi in hexane (10 M, 2.4 mL, 24 mmol) at -78 °C under nitrogen. After stirred at -78 °C for 30 minutes, a slurry was obtained and treated with triisopropyl borate (6.5 mL, 28 mmol). The reaction solution was slowly warmed to ambient temperature and quenched with 1N aqueous hydrochloric acid solution (60 mL). Ethyl acetate (100 mL) was added and organic layer was separated, and aqueous layer was extracted with ethyl acetate (3x60 mL). The combined organic layer was washed with brine and dried with MgSO₄. The solvent was removed *in vacuo* and the residue was purified by a silica gel flash chromatography (ethyl acetate:hexane/2:1) to afford (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid as a white solid (1.4g, 81%): mp 249-250 °C; ¹H-NMR (DMSO-d₆) δ 10.21 (s, 1H, D₂O exchangeable), 7.90-7.95 (br s, 2H, D₂O exchangeable), 7.67 (m, 2H), 6.79 (d, 1H, *J* = 7.8 Hz), 1.61 (s, 6H); MS (ESI) *m/z* 222([M+H]⁺, 87%).

20

EXAMPLE 4**6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one****(Procedure A)**

A mixture of 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (1.5g, 5.9 mmol), 3-chlorophenyl boronic acid (1.83g, 11.7 mmol), tetrakis(triphenylphosphine)-palladium (0) (0.35g, 0.3 mmol), and sodium carbonate (2.48g, 23.4 mmol) in a mixture of DME and water (40 mL/10 mL) was degassed to remove the oxygen and then heated at 85 °C under a blanket of nitrogen for 3 hours. The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammonium chloride solution (20 mL). Ethyl acetate (50 mL) was

25

30

added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3x15 mL). The combined organic layers were washed with brine and dried with MgSO₄. The solvent was removed *in vacuo* and the residue was purified by silica gel flash chromatography (hexane:ethyl acetate/2:1) to afford 6-(3-chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one as a yellowish solid (1.4g, 82%): mp 158-159 °C; ¹H-NMR (DMSO-d₆) δ 10.31 (s, 1H, D₂O exchangeable), 7.75 (s, 1H), 7.61 (m, 3H), 7.46 (t, 1H, J = 7.9 Hz), 7.39 (dd, 1H, J = 7.0, 1.1 Hz), 6.96 (d, 1H, J = 8.6 Hz), 1.68 (s, 6H); Anal. Calc. For C₁₆H₁₄ClNO₂·0.1 H₂O: C, 66.37, H, 4.94, N, 4.84. Found: C, 66.14, H, 4.61, N, 4.71.

10

EXAMPLE 5

6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one

(Procedure B)

A mixture of (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid (2.22g, 10 mmol), 1,3-dibromo-5-fluorobenzene (3.05g, 12 mmol), tetrakis(triphenylphosphine)palladium (0) (0.6g, 0.52 mmol), and sodium carbonate (2.2g, 21 mmol) in a mixture of DME and water (70 mL/15 mL) was degassed to remove the oxygen and then heated at 85 °C under a blanket of nitrogen for 3 hours. The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammonium chloride solution (20 mL). Ethyl acetate (100 mL) was added and organic layer was separated. The aqueous layer was extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with brine and dried with MgSO₄. The solvent was removed *in vacuo* and the residue was purified by a silica gel flash chromatography (hexane:ethyl acetate/1:1) to give 6-(3-bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one as a white solid (1.4g, 40%): mp 182-183 °C; ¹H-NMR (DMSO-d₆) δ 10.36 (s, 1H, D₂O exchangeable), 7.78 (s, 1H), 7.58-7.65 (m, 3H), 7.49 (dd, 1H, J = 8.3, 1.8 Hz), 6.96 (d, 1H, J = 8.5 Hz), 1.69 (s, 6H); ¹⁹F-NMR (DMSO-d₆) δ -112.46 (m, 1F); MS (CI) *m/z* 352([M+H]⁺, 78%), 350([M+H]⁺, 75%). Anal. Calc. For C₁₆H₁₃BrFNO₂: C, 54.88, H, 3.74, N, 4.00. Found: C, 54.83, H, 3.82, N, 3.95.

30

EXAMPLE 6

5 3-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-
fluorobenzonitrile

A mixture of 6-(3-bromo-5-fluorophenyl)-4,4-dimethyl-2H-benz[d][1,3]oxazin-2-one (1g, 2.8 mmol), zinc cyanide (0.2g, 1.7 mmol), and tetrakis(triphenylphosphine)-palladium (0) (0.2g, 0.17 mmol) in dry DMF (20 mL) was degassed to remove oxygen and was then heated at 85 °C under a blanket of nitrogen for 6.5 hours. The reaction solution was cooled to room temperature and poured onto a cold saturated aqueous ammonium chloride solution (100 mL). The white precipitate appeared and was collected on a filter. The white solid was washed with distilled water (3x20 mL) and dissolved in a mixture of ethyl acetate (10 mL) and methanol (10 mL). The solution was applied on a pad of silica gel and eluted with a mixture of ethyl acetate and hexane (1:1). After solvent was removed, 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile was obtained as a white solid (0.7g, 84%): mp 253-254 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H, D₂O exchangeable), 8.13 (s, 1H), 7.92 (m, 1H), 7.82 (m, 1H), 7.73 (m, 2H), 6.98 (d, 1H, *J* = 8.2 Hz), 1.68 (s, 6H); ¹⁹F-NMR (DMSO-d₆) δ -112.25 (m, 1F); MS (EI) *m/z* 296(M⁺, 65%); Anal. Calc. For C₁₇H₁₃FN₂O₂: C, 68.91, H, 4.42, N, 9.45. Found: C, 68.85, H, 4.58, N, 9.14.

EXAMPLE 7

25 4-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-2-
carbonitrile

The product was prepared, from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 4-bromo-2-thiophenecarbonitrile according to the procedure outlined in Example 5, as a yellowish solid: mp 230-231 °C (decomposed); ¹H-NMR (CDCl₃) δ 8.32 (s, 1H, D₂O exchangeable), 7.83 (d, 1H, *J* = 1.5 Hz), 7.61 (d, 1H, *J* = 1.4 Hz), 7.43 (dd, 1H, *J* = 8.2, 1.9 Hz), 7.29 (d, 1H, *J* = 1.8 Hz), 6.85 (d,

^1H , $J = 8.2$ Hz), 1.78 (s, 6H); MS (EI) m/z 283 ($[\text{M-H}]^-$, 100%); Anal. Calc. For $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2\text{S} \cdot 0.2 \text{H}_2\text{O}$: C, 62.57, H, 4.34, N, 9.73. Found: C, 62.48, H, 4.31, N, 9.64.

EXAMPLE 8

6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione

A mixture of 6-(3-chlorophenyl)-4,4-dimethyl-1,4-dihydro-benzo[d]-
5 [1,3]oxazin-2-one (0.15g, 0.5 mmol) and Lawesson's reagent (0.24g, 0.6 mmol) in
anhydrous o-xylene was heated at reflux under nitrogen for 3 hours. The solvent was
removed and the residue was purified by a flash chromatography (silica gel,
hexane:ethyl acetate/6:1) to afford the title compound as a white solid (80 mg, 52%):
mp 183-184 °C; ¹H-NMR (DMSO-d₆) δ 12.25 (s, 1H, D₂O exchangeable), 7.78 (t,
10 1H, J = 1.7 Hz), 7.63-7.70 (m, 3H), 7.49 (t, 1H, J = 7.8 Hz), 7.42 (d, 1H, J = 8.1 Hz),
7.12 (d, 8.8 Hz), 1.72 (s, 6H); MS (EI) m/z 303 (M⁺, 100%), 305 (M⁺, 32%); Anal.
Calc. For C₁₆H₁₄ClNOS: C, 63.26, H, 4.64, N, 4.61. Found: C, 63.37, H, 4.62, N,
4.54.

15

EXAMPLE 9

4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-2-carbonitrile

A mixture of 4-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-
yl)-thiophene-2-carbonitrile (0.23g, 0.8 mmol) and Lawesson's reagent (0.38g, 0.96
20 mmol) in anhydrous o-xylene was heated to reflux under nitrogen for 3 hours. The
solvent was removed *in vacuo* and the residue was purified by a flash chromatography
(silica gel, hexane:ethyl acetate/3:1) to afford the title compound as a yellow solid (85
mg, 35%): mp 242-243 °C; ¹H-NMR (DMSO-d₆) δ 12.22 (s, 1H, D₂O exchangeable),
8.50 (d, 1H, J = 1.2 Hz), 8.37 (d, 1H, J = 1.0 Hz), 7.71 (m, 2H), 7.09 (d, 1H, J = 8.0
25 Hz), 1.69 (s, 6H); MS (APCI) m/z 301 ([M+H]⁺, 100%); Anal. Calc. For
C₁₅H₁₂N₂OS₂: C, 59.97, H, 4.03, N, 9.33. Found: C, 59.67, H, 3.85, N, 9.14.

EXAMPLE 10

6-Bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione

30 The product was prepared, from 6-bromo-4,4-dimethyl-1,4-dihydro-
benzo[d][1,3]oxazin-2-one and Lawesson's reagent using the procedure of Example 9,

as a white solid: mp 221-222.5 °C; ¹H-NMR (CDCl₃) δ 9.38 (s, 1H, D₂O exchangeable), 7.42 (dd, 1H, *J* = 8.5, 2.1 Hz), 7.29 (d, 1H, *J* = 2.0 Hz), 6.76 (d, 1H, *J* = 8.4 Hz), 1.76 (s, 6H); MS (EI) *m/z* 272 ([M+H]⁺, 94%), 274 ([M+H]⁺, 100%).

5

EXAMPLE 11**3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile**

The product was prepared, from 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile and Lawesson's reagent using the
10 procedure of Example 9, as a yellow solid: 248-249 °C; ¹H-NMR (DMSO-*d*₆) δ 12.3 (s, 1H), 8.15 (bs, 1H), 8.02 (d, 1H, *J* = 10.48 Hz), 7.85-7.78 (m, 3H), 7.13 (d, 1H, *J* = 8.92 Hz), 1.71 (s, 6H); MS (APCI) *m/z* 313([M+H]⁺, 100%); Anal. Calc. For C₁₇H₁₃FN₂OS: C, 65.37, H, 4.19, N, 8.97. Found: C, 65.26, H, 4.31, N, 8.61.

15

EXAMPLE 12**3-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile**

A mixture of (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid (2.22g, 10 mmol), 3-bromobenzonitrile (2.18 g, 12 mmol),
tetrakis(triphenylphosphine)palladium (0) (0.6g, 0.52 mmol), and sodium carbonate
20 (2.2g, 21 mmol) in a mixture of DME and water (70 mL/15 mL) was degassed to remove the oxygen and then heated at 85 °C under a blanket of nitrogen for 3 hours. The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammonium chloride solution (20 mL). Ethyl acetate (100 mL) was added and the organic layer was separated. The aqueous layer was extracted with
25 ethyl acetate (3x30 mL). The combined organic layers were washed with brine and dried with MgSO₄. The solvent was removed *in vacuo* and the residue was purified by a silica gel flash chromatography (hexane:ethyl acetate/1:1) to give 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile as an off-white solid (0.7g, 25%): mp 236-237 °C; ¹H-NMR (DMSO-*d*₆) δ 10.34 (s, 1H, D₂O
30 exchangeable), 8.21 (s, 1H), 8.02 (d, 1H, *J* = 8.1 Hz), 7.79 (d, 1H, *J* = 7.7 Hz), 7.60-

7.70 (m, 3H), 6.98 (d, 1H, $J = 8.2$ Hz), 1.71 (s, 6H); Anal. Calc. For $C_{17}H_{14}N_2O_2 \cdot 0.1 H_2O$: C, 72.89, H, 5.11, N, 10.00. Found: C, 72.75, H, 5.05, N, 9.65.

EXAMPLE 13

5 **3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile**

A mixture of 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile (1 g, 3.6 mmol) and Lawesson's reagent (1.8 g, 4.3 mmol) in *o*-xylene (30 mL) was heated at reflux overnight. The reaction mixture was cooled to room temperature, poured into ethyl acetate (50 mL) and washed with 1 N HCl (2x20 mL).


10 The organic layer was dried over sodium sulfate and concentrated. The residue was purified *via* flash chromatography (silica gel, 20% ethyl acetate/hexane) to give 3-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile (0.21 g, 20%) as a white solid: mp 236-237°C; 1H -NMR (DMSO- d_6) δ 12.3 (s, 1H), 8.24 (s, 1H), 8.05 (d, 1H, $J = 8.07$ Hz), 7.82 (d, 1H, $J = 7.68$ Hz), 7.74-7.64 (m, 3H), 7.14 (d, 1H, $J = 8.78$ Hz), 1.71 (s, 6H); MS (APCI) m/z 295 ($[M + H]^+$, 100%); Anal. Calc. For $C_{17}H_{14}N_2OS$: C, 69.36, H, 4.79, N, 9.52. Found: C, 68.35, H, 4.91, N, 9.07

EXAMPLE 14

20 **Potency in the relevant assays**

The compounds of this invention were tested in the relevant assay as described below and their potency are in the range of 0.01 nM to 5 μ M in the *in vitro* assays and 0.001 to 300 mg/kg in the *in vivo* assays. The selected examples are listed in Table 1 below.

25

Table 1

5	Compound	R ₁	R ₂	R ₃	hPR CV-1 EC ₅₀ (nM)	Ovulation Inhibition ED ₁₀₀ (mg/kg)
10	1	3-chlorophenyl	Me	Me	0.65	ND*
	2	4-(2-cyanothio- phenyl)	Me	Me	0.3	1
15	3	3-cyano-5-fluoro- phenyl	Me	Me	5.1	ND
	4	3-cyanophenyl	Me	Me	0.4**	

20 * ND, not determined; ** alkaline phosphatase data.

(1) T47D cell proliferation assay

The objective of this assay is the determination of progestational and antiprogestational potency by using a cell proliferation assay in T47D cells. A compound's effect on DNA synthesis in T47D cells is measured. The materials and methods used in this assay are as follows.

a. Growth medium: DMEM:F12 (1:1) (GIBCO, BRL) supplemented with 10% (v/v) fetal bovine serum (not heat-

inactivated), 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

b. Treatment medium: Minimum Essential

Medium (MEM) (#51200-038 GIBCO, BRL) phenol red-free supplemented with 0.5% charcoal stripped fetal bovine serum, 100U/ml penicillin, 200 mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

c. Cell culture

Stock T47 D cells are maintained in growth medium. For BrdU incorporation assay, cells are plated in 96-well plates (Falcon, Becton Dickinson Labware) at 10,000 cells/well in growth medium. After overnight incubation, the medium is changed to treatment medium and cells are cultured for an additional 24 hr before treatment. Stock compounds are dissolved in appropriate vehicle (100% ethanol or 50% ethanol/50% DMSO), subsequently diluted in treatment medium and added to the cells. Progesterone and antiprogesterone reference compounds are run in full dose-response curves. The final concentration of vehicle is 0.1%. In control wells, cells receive vehicle only. Antiprogesterones are tested in the presence of 0.03 nM trimegestone, the reference progesterone agonist. Twenty-four hours after treatment, the medium is discarded and cells are labeled with 10 mM BrdU (Amersham Life Science, Arlington Heights, IL) in treatment medium for 4 hr.

d. Cell Proliferation Assay

At the end of BrdU labeling, the medium is removed and BrdU incorporation is measured using a cell proliferation ELISA kit (#RPN 250, Amersham Life Science) according to manufacturer's instructions. Briefly, cells are fixed in an ethanol containing fixative for 30 min, followed by incubation in a blocking buffer for 30 min to reduce background. Peroxidase-labeled anti-BrdU antibody is added to the wells and incubated for 60 min. The cells are rinsed three times with PBS and incubated with 3,3',5,5'-tetramethylbenzidine (TMB) substrate for 10-20 min depending upon the potency of tested compounds. Then 25 µl of 1 M sulfuric acid is added to each well to stop color reaction and optical density is read in a plate reader at 450 nm within 5 min.

e. Analysis of Results:

Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC₅₀ or IC₅₀ values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way
 5 analysis of variance and non-linear dose response analyses in both single dose and dose response studies.

f. Reference Compounds:

Trimegestone and medroxyprogesterone acetate (MPA) are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run
 10 in full dose-response curves and the EC₅₀ or IC₅₀ values are calculated.

Table 2. Estimated EC₅₀, standard error (SE), and 95% confidence intervals (CI) for individual studies

Compound	Exp	EC ₅₀		95% CI	
		(nM)	SE	lower	upper
Trimegestone	1	0.017	0.003	0.007	0.040
	2	0.014	0.001	0.011	0.017
	3	0.019	0.001	0.016	0.024
MPA	1	0.019	0.001	0.013	0.027
	2	0.017	0.001	0.011	0.024

Table 3. Estimated IC₅₀, standard error, and 95% confident interval for the antiprogestin, RU486

Compound	Exp	IC ₅₀		95% CI	
		(nM)	SE	lower	upper
RU486	1	0.011	0.001	0.008	0.014
	2	0.016	0.001	0.014	0.020
	3	0.018	0.001	0.014	0.022

EC₅₀: Concentration of a compound that gives half-maximal increase in BrdU incorporation with SE; IC₅₀: Concentration of a compound that gives half-maximal decrease in 0.1 trimegestone induced BrdU incorporation with SE

5 (2) Rat decidualization assay The objective of this procedure is used to evaluate the effect of progestins and antiprogestins on rat uterine decidualization and compare the relative potencies of various test compounds. The materials and methods used in this assay are as follows.

10 a. Methods: Test compounds are dissolved in 100% ethanol and mixed with corn oil (vehicle). Stock solutions of the test compounds in oil (MazolaTM) are then prepared by heating (~80 °C) the mixture to evaporate ethanol. Test compounds are subsequently diluted with 100% corn oil or 10% ethanol in corn oil prior to the treatment of animals. No difference in decidual response was found when these two vehicles were compared.

15 b. Animals (RACUC protocol #5002)
Ovariectomized mature female Sprague-Dawley rats (~60-day old and 230g) are obtained from Taconic (Taconic Farms, NY) following surgery. Ovariectomy is performed at least 10 days prior to treatment to reduce circulating sex steroids. Animals are housed under 12 hr light/dark cycle and given standard rat chow and
20 water ad libitum.

 c. Treatment
Rats are weighed and randomly assigned to groups of 4 or 5 before treatment. Test compounds in 0.2 ml vehicle are administered by subcutaneous injection in the nape of the neck or by gavage using 0.5 ml. The animals are treated
25 once daily for seven days. For testing antiprogestins, animals are given the test compounds and a EC₅₀ dose of progesterone (5.6 mg/kg) during the first three days of treatment. Following decidual stimulation, animals continue to receive progesterone until necropsy four days later.

 d. Dosing
30 Doses are prepared based upon mg/kg mean group body weight. In all studies, a control group receiving vehicle is included. Determination of

dose-response curves is carried out using doses with half log increases (e.g. 0.1, 0.3, 1.0, 3.0 mg/kg).

e. Decidual induction

Approximately 24 hr after the third injection,
5 decidualization is induced in one of the uterine horns by scratching the antimesometrial luminal epithelium with a blunt 21 G needle. The contralateral horn is not scratched and serves as an unstimulated control. Approximately 24 hr following the final treatment, rats are sacrificed by CO₂ asphyxiation and body weight measured. Uteri are removed and trimmed of fat. Decidualized (D-horn) and control (C-horn) uterine
10 horns are weighed separately.

f. Analysis of Results:

The increase in weight of the decidualized uterine horn is calculated by D-horn/C-horn and logarithmic transformation is used to maximize normality and homogeneity of variance. The Huber M-estimator is used to down
15 weight the outlying transformed observations for both dose-response curve fitting and one-way analysis of variance. JMP software (SAS Institute, Inc.) is used for both one-way ANOVA and non-linear dose-response analyses.

g. Reference Compounds:

All progestin reference compounds were run in full dose-
20 response curves and the EC₅₀ for uterine wet weight were calculated.

Table 4. Estimated EC₅₀, standard error (SE), and 95% confidence intervals for individual studies

Compound	Exp	EC ₅₀ (mg/kg. s.c.)	SE	95% CI	
				lower	upper
Progesterone	1	5.50	0.77	4.21	7.20
	2	6.21	1.12	4.41	8.76
3-Ketodesogestrel	1	0.11	0.02	0.07	0.16
	2	0.10	0.05	0.11	0.25
	3	0.06	0.03	0.03	0.14

5	Levonorgestrel	1	0.08	0.03	0.04	0.16
		2	0.12	0.02	0.09	0.17
		3	0.09	0.02	0.06	0.13
		4	0.09	0.02	0.06	0.14
10	MPA	1	0.42	0.03	0.29	0.60
		2	0.39	0.05	0.22	0.67
		3	0.39	0.04	0.25	0.61

Table 5. Estimated average EC₅₀, standard error, and 95% confidence intervals for dose-response curves of 3 reference compounds

15	<u>EC₅₀</u>		<u>95% CI</u>	
	Compound	(mg/kg, s.c.) SE	lower	upper
	Progesterone	5.62 0.62	4.55	7.00
	3-Ketodesogestrel	0.10 0.02	0.07	0.14
	Levonorgestrel	0.10 0.01	0.08	0.12

20

Table 6. Estimated IC₅₀, standard error, and 95% confident interval for the antiprogesterin, RU 486

25	<u>IC₅₀</u>		<u>95% CI</u>	
	Compound	Exp. (mg/kg, p.o.) SE	lower	upper
	RU 486	1 0.21 0.07	0.05	0.96
		2 0.14 0.02	0.08	0.27

30

Concentration: Compound concentration in assay(default-mg/kg body weight)

Route of administration: Route the compound is administered to the animals

Body weight: Mean total animal body weight (default-kg)

D-horn: Wet weight of decidualized uterine horn (default-mg)

C-horn: Wet weight of control uterine horn (default-mg)

Decidual response: $[(D-C)/C] \times 100\%$

- 5 Progestational activity: Compounds that induce decidualization significantly ($p < 0.05$) compared to vehicle control are considered active

Antiprogesterone activity: Compounds that decrease EC_{50} progesterone induced decidualization significantly ($p < 0.05$)

- 10 EC_{50} for uterine weight: Concentration of compound that gives half-maximal increase in decidual response (default-mg/kg)

IC_{50} for uterine weight: Concentration of compound that gives half-maximal decrease in EC_{50} progesterone induced decidual response (default-mg/kg)

(3) PRE-luciferase assay in CV-1 cells

- 15 The object of this assay is to determine a compound's progestational or antiprogesterone potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids. The materials methods used in the assay are as follows.

- a. Medium: The growth medium was as follows: DMEM
20 (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL). The experimental medium was as follows: DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin,
25 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

b. Cell culture, transfection, treatment, and luciferase assay

- Stock CV-1 cells are maintained in growth medium. Co-transfection is done using 1.2×10^7 cells, 5 mg pLEM plasmid with hPR-B inserted at SphI and BamHI sites, 10 mg pGL3 plasmid with two PREs upstream of the
30 luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml. Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II.

After electroporation, cells are resuspended in growth medium and plated in 96-well plate at 40,000 cells/well in 200 μ l. Following overnight incubation, the medium is changed to experimental medium. Cells are then treated with reference or test compounds in experimental medium. Compounds are tested for antiprogesterational activity in the presence of 3 nM progesterone. Twenty-four hr. after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL). Fifty μ l of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 min in a Titer Plate Shaker (Lab Line Instrument, Inc.). Luciferase activity is measured using luciferase reagents from Promega.

10 c. Analysis of Results:

Each treatment consists of at least 4 replicates. Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC₅₀ or IC₅₀ values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear response analyses.

15 d. Reference Compounds:

Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogesterin. All reference compounds are run in full dose-response curves and the EC₅₀ or IC₅₀ values are calculated.

20 **Table 8. Estimated EC₅₀, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies**

Compound	Exp.	EC ₅₀	SE	95% CI	
		(nM)		lower	upper
Progesterone	1	0.616	0.026	0.509	0.746
	2	0.402	0.019	0.323	0.501
	3	0.486	0.028	0.371	0.637
Trimegestone	1	0.0075	0.0002	0.0066	0.0085
	2	0.0081	0.0003	0.0070	0.0094

3 0.0067 0.0003 0.0055 0.0082

Table 9. Estimated IC₅₀, standard error (SE), and 95% confident interval (CI) for the antiprogesterin, RU486 from three individual studies

5

Compound	Exp.	IC 50	SE	95% CI	
		(nM)		lower	upper
RU486	1	0.028	0.002	0.019	0.042
	2	0.037	0.002	0.029	0.048
	3	0.019	0.001	0.013	0.027

10

Progestational activity: Compounds that increase PRE-luciferase activity significantly ($p < 0.05$) compared to vehicle control are considered active.

Antiprogesterational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly ($p < 0.05$). EC₅₀: Concentration of a compound that gives half-maximal increase PRE-luciferase activity (default-nM) with SE.

15

IC₅₀: Concentration of a compound that gives half-maximal decrease in 3 nM progesterone induced PRE-luciferase activity (default-nM) with SE.

20

EXAMPLE 15

WAY-166494: 6-(3-fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

4-Amino-3'-fluoro[1,1'-biphenyl]-3-carbonitrile was prepared from 3-fluorophenyl boronic acid and 2-amino-5-bromobenzonitrile according to the procedure of Example 4. A solution of 4-amino-3'-fluoro[1,1'-biphenyl]-3-carbonitrile (6.65g, 31.3 mmol) in anhydrous THF (100 mL) was treated drop wise at room temperature under nitrogen with methylmagnesium bromide (3.0 M in ether, 21 mL, 63 mmol). The reaction mixture was then heated at gentle reflux for 1.5 hours, cooled to room temperature, and treated with 3N aqueous hydrogen chloride solution (30 mL). The resulted mixture was heated at reflux for 3 hours, cooled to ambient temperature, and adjusted to a pH of 5-6 by the addition of a saturated aqueous sodium carbonate solution. Ethyl acetate (100 mL) was added, the organic layer was

25

30

separated and the aqueous layer was extracted with ethyl acetate (3x50 mL). The combined organic layers were dried (MgSO₄) and evaporated. The residue was purified by a silica gel chromatography (hexane:ethyl acetate/3:1) to afford 1-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)ethanone (3.1g, 43%): mp 156-157 °C.

- 5 A solution of 1-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)ethanone (3g, 13 mmol) in anhydrous methanol (60 mL) was then treated at room temperature under nitrogen with sodium borohydride in a portion wise manner. After addition, the reaction mixture was stirred for 4 hours, treated with a saturated solution of aqueous ammonium sulfate (50 mL) and ethyl acetate (100 mL). The organic layer was
10 separated, dried (MgSO₄), and evaporated *in vacuo*. The residue was purified on a silica gel chromatography (hexane:ethyl acetate/3:1) to yield 1-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)ethanol as a white solid (2g, 67%): mp 136-137 °C.

- A mixture of the above alcohol (0.2g, 0.87 mmol) and triphosgene in anhydrous THF (20 mL) was stirred at room temperature under nitrogen. After 15
15 minutes, the mixture was treated with a saturated aqueous sodium bicarbonate solution (30 mL) and ethyl acetate (40 mL). The organic layer was separated, dried (MgSO₄), and evaporated to give 6-(3-fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as a white solid (0.18g, 81%): mp 160-161 °C; ¹H-NMR (DMSO-*d*₆) δ 10.31 (s, 1H), 7.62 (dd, 1H, *J* = 8.2, 1.9 Hz), 7.57 (s, 1H), 7.44-7.53 (m, 3H), 7.13-7.20 (m
20 1H), 6.97 (d, 1H, *J* = 8.2 Hz), 5.57 (q, 1H, *J* = 6.6 Hz), 1.63 (d, 3H, *J* = 6.6 Hz). MS (ESI) *m/z* 256 [M - H]⁺.

- A solution of 6-(3-fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (0.15g, 0.58 mmol) in toluene was treated with Lawesson's reagent according to the procedure in example 9 to yield 6-(3-fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-thione (0.08g, 50%) as an off-white solid (0.08g, 50%): mp 173-174 °C;
25 ¹H-NMR (DMSO-*d*₆) δ 12.27 (s, 1H), 7.70 (dd, 1H, *J* = 8.2, 2.0 Hz), 7.62 (s, 1H), 7.46-7.56 (m, 3H), 7.15-7.22 (m, 1H), 7.11 (d, 1H, *J* = 8.3 Hz), 5.64 (q, 1H, *J* = 6.6 Hz), 1.67 (d, 3H, *J* = 6.6 Hz); MS (ESI) *m/z* 272 [M - H]⁺.

EXAMPLE 16

5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile

5 5-(4, 4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-methylthiophene-2-carbonitrile was prepared, according to the procedure in Example 5 using (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 5-bromo-4-methyl-2-thiophenecarbonitrile, as an off-white solid: mp 195-200 °C; ¹H-NMR (DMSO-d₆) δ 10.2 (s, 1H), 8.32 (s, 1H), 7.41-7.44 (m, 2H), 7.01 (d, 1H, J = 8.8 Hz), 2.28 (s, 3H), 1.64 (s, 6H); MS (APCI) m/z 299 [M+H]⁺; Anal. Calc. For C₁₆H₁₄N₂O₂S; C, 64.41; H, 4.75; N, 8.89. Found: C, 64.64; H, 4.62; N, 9.39.

10 To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile (5g, 16.7 mmol) in anhydrous toluene was added, at room temperature under a blanket of nitrogen, Lawesson's reagent (6g, 14.8 mmol). The reaction mixture was heated at reflux for 2 hrs, allowed to cool to room temperature, and solvent was removed *in vacuo*. The residue was purified by a silica gel column chromatography (THF:hexane/1:3) to yield the title compound as a yellowish solid (2.4g, 46%): mp 211-212 °C; ¹H-NMR (DMSO-d₆) δ 12.3 (s, 1H), 7.88 (s, 1H), 7.46-7.52 (m, 2H), 7.16 (d, 1H, J = 8.3 Hz), 2.30 (s, 3H), 1.68 (s, 6H); MS (ESI) m/z 313 [M-H]⁻; Anal. Calc. For C₁₆H₁₄N₂OS₂; C, 61.12; H, 4.49; N, 8.91. Found: C, 60.91; H, 4.48; N, 8.66.

EXAMPLE 17

tert-Butyl 2-cyano-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylate

25 A solution of 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (5.0 g, 20 mmol) and tetrakis(triphenylphosphine)palladium(0) (580 mg, 0.5 mmol) in toluene (200 mL) was stirred under a flow of nitrogen for 25 min. To the solution was added sequentially 1-tert-butoxycarbonylpyrrole-2-boronic acid (8.24 g, 39 mmol) in absolute ethanol (50 mL) and potassium carbonate (5.39 g, 39 mmol) in water (50 mL). The mixture was heated to 80 °C for 16 h and allowed to cool. The reaction mixture was poured into an aqueous saturated sodium bicarbonate solution (200 mL).

and extracted with ethyl acetate (3 x 200 mL). The organic layers were combined, washed with water (200 mL) and brine (100 mL) and dried over magnesium sulfate. The solution was filtered, concentrated *in vacuo*, and the residue was purified by flash column chromatography on silica gel (30% ethyl acetate/hexane) to give 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-pyrrole-1-carboxylic acid tert-butyl ester (4.0 g, 58%) as a tan solid, mp 172-173 °C.

To a solution of 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-pyrrole-1-carboxylic acid *tert*-butyl ester (2.0 g, 5.8 mmol) in THF (anhydrous, 50 mL) at -78 °C was added chlorosulfonyl isocyanate (0.66 mL, 6.7 mmol). After 90 min, DMF (9 mL, 116 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and the product was extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid tert-butyl ester (1.1 g, 52%) as a white powder, mp 165-167 °C; ¹H NMR (DMSO-*d*₆) δ 1.36 (s, 9H), 1.61 (s, 6 H), 6.44 (d, 1 H, *J* = 3.7 Hz), 6.92 (d, 1 H, *J* = 8.2 Hz), 7.27-7.32 (m, 2 H), 7.36 ('d', 1 H, *J* = 1.5 Hz), 10.36 (s, 1 H); MS (EI) *m/z* 367 [M]⁺.

To 2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid tert-butyl ester (1.3 g, 35 mmol, 1 eq) in toluene (130 mL) was added Lawesson's reagent (1.58 g, 3.9 mmol, 1.1 eq) and the reaction mixture was heated to 80 °C for 2 h. The solvent was removed *in vacuo* and the residue was dissolved in acetone/dichloromethane and adsorbed onto silica gel. Purification by flash column chromatography (10% ethyl acetate/hexane) gave the product (0.51 g, 38%) as yellow crystals. ¹H NMR (DMSO-*d*₆) δ 1.35 (s, 9 H), 1.64 (s, 6 H), 6.47 (d, 1 H, *J* = 3.6 Hz), 7.07 (d, 1 H, *J* = 8.1 Hz), 7.32 (d, 1 H, *J* = 3.6 Hz), 7.37 (dd, 1 H, *J* = 1.8, 8.1 Hz), 7.43 (d, 1 H, *J* = 1.8 Hz), 12.28 (s, 1 H); MS (ESI) [M-H]⁻ = 382; Anal. Calcd. For C₂₀H₂₁N₃O₃S: C, 62.64; H, 5.52; N, 10.96. Found: C, 62.53; H, 5.6; N, 10.87.

EXAMPLE 18

5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile

To a solution of tert-butyl 2-cyano-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylate (0.5 g, 1.3 mmol, 1 eq) in THF (5 mL) was added NaOEt (0.27 g, 3.9 mmol, 3 eq) in EtOH (5 mL) and the reaction was heated to 80°C for 2 h. The solvents were removed *in vacuo* and the residue partitioned between ethyl acetate (100 mL) and water (100 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (100 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification by flash column chromatography (10% ethyl acetate/hexane) gave the title compound (0.27g, 73%) as a brown powder, mp 261-262 °C. ¹H NMR (DMSO-*d*₆) δ 1.68 (s, 6 H), 6.72 – 6.73 (m, 1 H), 6.99 – 7.01 (m, 1 H), 7.06 (d, 1 H, *J* = 7.9 Hz), 7.66 – 7.70 (m, 2 H), 12.26 (s, 1 H), 12.62 (s, 1 H); MS (ESI) [M-H]⁺ = 282; Anal. Calcd. For C₁₅H₁₃N₃OS: C, 63.58; H, 4.62; N, 14.83. Found: C, 63.25; H, 4.78; N, 15.11.

EXAMPLE 19

[6-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile

[6-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile was prepared, according to the procedure of Example 5 using (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and (6-bromo-2-pyridyl)acetonitrile (*J. Org. Chem.* 1988, 53, 786-790), as an off-white solid: mp 210-212.5 °C; ¹H NMR (DMSO-*d*₆) δ 1.68 (s, 6 H), 4.27 (s, 2 H), 7.00 (d, 1 H, *J* = 8.3 Hz), 7.34 (d, 1 H, *J* = 7.1 Hz), 7.89 – 7.96 (m, 2 H), 8.00 – 8.05 (m, 2 H), 10.42 (s, 1 H); MS (ESI) [M-H]⁺ = 292; Anal. Calcd. For C₁₇H₁₅N₃O₂: C, 69.61; H, 5.15; N, 14.33. Found: C, 68.49; H, 5.19; N, 13.74.

To [6-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile (80 mg, 0.27 mmol, 1 eq) in *p*-xylene (10 mL) was added Lawesson's reagent (55 mg, 0.14 mmol, 0.5 eq) and the reaction was heated to reflux for 2 hours.

The reaction was cooled to room temperature and adsorbed onto silica gel.

Purification by flash column chromatography (50% ethyl acetate/hexane) on silica gel gave the title compound (40 mg, 48%) as an off-white solid: mp 215-217 °C; ¹H NMR (*d*₆-DMSO, 300 MHz) δ 1.71 (s, 6 H), 4.28 (s, 2 H), 7.15 (d, 1 H, *J* = 8.3 Hz), 7.36 (d, 1 H, *J* = 7.3 Hz), 7.89 - 7.99 (m, 2 H), 8.04 - 8.11 (m, 2 H), 12.32 (s, 1 H); MS (ESI) [M-H]⁻ = 308; Anal. calcd. for C₁₇H₁₅N₃OS: C, 66.00; H, 4.89; N, 13.58. Found: C, 64.43; H, 4.65; N, 12.95.

EXAMPLE 20

10 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile

2-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3] oxazin-6-yl)-5-cyano-pyrrole-1-carboxylic acid *tert*-butyl ester (1 g, 2.7 mmol) was placed in a 25 mL round bottomed flask stoppered with a rubber septum and equipped with nitrogen inlet and a
15 needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 160 °C. After 20 min at this temperature, the flask was removed from the oil bath and allowed to cool. The yellow residue was washed into a larger flask with dichloromethane/ethyl acetate and adsorbed onto a small amount of silica gel. Purification by flash column chromatography on silica gel
20 (40% ethyl acetate/hexane) gave of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile (340 mg, 47%) as a yellow powder: mp 241-242 °C; ¹H NMR (*d*₆-DMSO, 300 MHz) δ 1.65 (s, 6 H), 6.67 (d, 1 H, *J* = 3.9 Hz), 6.91 (d, 1 H, *J* = 8.3 Hz), 6.98 (d, 1 H, *J* = 3.9 Hz), 7.61 (dd, 1 H, *J* = 1.8, 8.3 Hz), 7.65 ('d', 1 H, *J* = 1.6 Hz), 10.32 (s, 1 H), 12.54 (bs, 1 H); MS (EI) *m/z* 267 M⁺;
25 Anal. Calcd. For C₁₅H₁₃N₃O₂: C, 67.41; H, 4.90; N, 15.72. Found: C, 67.19; H, 4.96; N, 15.35.

To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile (1 eq, 71 mg, 0.27 mmol) in dimethylformamide (0.5 mL) was added potassium carbonate (5 eq, 0.18 g, 0.135 mmol). After 10 min,
30 iodomethane (3 eq, .05 mL, 0.81 mmol) was added and the suspension was stirred for

2 hours, poured into water (5 mL) and the product was extracted with ethyl acetate (3 x 5 mL). The layers were then separated, the aqueous layer extracted with ethyl acetate (3 x 10 mL) and the combined organic layer was washed with brine, dried over MgSO₄ and purified by flash column chromatography on silica gel eluting with 30% ethyl acetate/hexane to give 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile (30 mg, 41%) as a white solid; MS (ES) *m/z* 280 (M-H)⁺; Anal. Calcd For C₁₆H₁₅N₃O₂: C, 68.3, H, 5.37, N, 14.9. Found, C, 68.4, H, 5.51, N, 14.6.

To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile (6.0 g, 22 mmol, 1 eq) in toluene (600 mL) was added Lawesson's reagent (5.9 g, 15 mmol, 0.65 eq) and the reaction was heated to 80 °C for 2 hours. The reaction was cooled to room temperature, poured into water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated *in vacuo*. Purification by flash column chromatography (5-10% ethyl acetate/hexane) gave the title compound (2.0 g, 31 %) as a slightly yellow solid: mp 225-228 °C. ¹H NMR (*d*₆-DMSO, 300 MHz) δ 1.67 (s, 6 H), 3.72 (s, 3 H), 6.37 (dd, 1 H, *J* = 0.8, 4.1 Hz), 7.04 (dd, 1 H, *J* = 0.8, 4.1 Hz), 7.13 (m, 1 H), 7.47 (m, 2 H), 12.30 (s, 1 H); MS (ESI) [M-H]⁺ = 296; Anal. calcd. for C₁₆H₁₅N₃OS: C, 64.62; H, 5.08; N, 14.13. Found: C, 64.7; H, 5.12; N, 14.17.

EXAMPLE 21

5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbothiamide

To 4,4-dimethyl-6-(5-cyano-1H-pyrrol-2-yl)-1,4-dihydrobenzo [d][1,3]oxazin-2-one (6.0 g, 22.5 mmol) in *p*-xylene (100 mL) was added Lawesson's reagent (5.9 g, 14.6 mmol, 0.65 eq) and the reaction was heated to reflux for 3 hours. The reaction was cooled to room temperature, concentrated *in vacuo*, and adsorbed onto silica gel. Purification by flash column chromatography (30% ethyl acetate/hexane) on silica gel gave the title compound (1.2 g, 17%) as a yellow powder: ¹H NMR (DMSO-*d*₆)

□ 1.69 (s, 6 H), 6.65 (dd, 1 H, $J = 2.2, 3.8$ Hz), 6.98 (dd, 1 H, $J = 2.2, 3.8$ Hz), 7.03 (d, 1 H, $J = 8.2$ Hz), 7.69 (dd, 1 H, $J = 1.6, 8.2$ Hz), 7.81 (d, 1 H, $J = 1.6$ Hz), 8.92 (s, 1 H), 9.09 (s, 1H), 11.19 (s, 1 H), 12.22 (s, 1 H); MS (ESI) $[M+H]^+ = 318$, $[M-H]^- = 316$; Anal. calcd. for $C_{15}H_{15}N_3OS_2$: C, 56.76; H, 4.76; N, 13.24. Found: C, 56.78; H, 4.87; N, 12.54.

EXAMPLE 22

5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl) thiophene-3-carbonitrile

10 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-3-carbonitrile was prepared, according to the procedure in Example 5 using (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 2-bromo-4-thiophenecarbonitrile, as an off-white solid: mp 255-260 °C; 1H -NMR (DMSO- d_6) δ 10.36 (s, 1H), 8.48(d, 1H, $J = 1.1$ Hz), 7.88-7.87 (d, 1H $J = 1.3$ Hz), 7.63 (d, 1H $J =$
15 1.9 Hz), 7.56-7.54 (dd, 1H, $J = 8.0, 2.0$ Hz), 6.93 (d, 1H, $J = 8.1$ Hz), 1.64 (s, 6H); MS(-ESI) m/z 283 (M-H).

The title compound was prepared in a manner similar to Example 16 using 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl) thiophene-3-carbonitrile and Lawesson's reagent. The product was obtained in the form of yellow
20 crystals: m.p. 258-259 °C. 1H NMR (DMSO- d_6) δ 12.3 (s, 1 H), 8.54 (d, 1H, $J = 0.9$ Hz), 7.96 (s, 1H), 7.69-7.62 (m, 2H), 7.11-7.08 (d, 1 H, $J = 8.3$ Hz), 1.69 (s, 6H); MS (ESI) m/z 299 [M-H] $^-$; Anal. Calcd. For $C_{15}H_{12}N_2OS_2 \cdot \frac{1}{2} H_2O$: C, 58.0; H, 4.24; N, 9.05. Found C, 58.33; H, 3.85; N, 8.39.

25

EXAMPLE 23

5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile

To a solution of 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile (1.3 g, 5 mmol) in dimethylformamide (25 ml) was added
30 potassium carbonate (1 g, 7.5 mmol), and iodomethane (0.4 ml, 5.1 mmol), and the mixture was stirred at room temperature for 3 hours. The mixture was triturated with

ethyl acetate/water, and the ethyl acetate layer was separated, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was recrystallized from ethyl acetate/hexane to afford 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile (0.4 g, 27%): m.p. 200-202 °C; ¹H-NMR (DMSO-_d₆) δ 1.25 (t, *J* = 7.2 Hz, 3H), 1.64 (s, 6H), 4.07 (q, *J* = 7.2 Hz, 2H), 6.29 (d, *J* = 4.1, Hz, 1H), 7.0 (d, *J* = 8 Hz, 1H), 7.05 (d, *J* = 4.1 Hz, 1H), 7.34 (m, 2H), 10.42 (s, 1H); MS (ESI) *m/z* 294 (M-H).

The title compound was prepared according to the procedure for Example 16 from 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile and Lawesson's reagent. The product was obtained in the form of white needles: mp 212-213 °C; ¹H-NMR (DMSO-_d₆) δ 1.25 (t, 3H, *J* = 7 Hz), 1.68 (s, 6H), 4.07 (q, *J* = 7 Hz, 2H), 6.32 (d, *J* = 3.9 Hz, 1H), 7.07 (d, *J* = 3.9 Hz, 1H), 7.15 (d, *J* = 9 Hz, 1H), 7.42 (m, 2H), 12.33 (s, 1H); MS (ESI) *m/z* 310 (M-H).

15

EXAMPLE 23

4-(1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazin-4,1-cyclohexan]-6-yl)-2-thiophenecarbonitrile

1-(2-Amino-5-bromo-phenyl) cyclohexanol was prepared, according to the procedure of Example 1 using 2-amino-5-bromobenzoic acid and the Grignard reagent prepared from 1,5-dibromopentane, as a clear oil: ¹H-NMR (DMSO-_d₆) δ 7.07 (d, 1H, *J* = 2.3 Hz), 7.03 (dd, 1H, *J* = 8.4, 2.4 Hz), 6.55 (d, 1H, *J* = 8.6 Hz), 5.49 (s, 2H, D₂O exchangeable), 5.00 (s, 1H, D₂O exchangeable), 2.01 (d, 2H, *J* = 1.8 Hz), 1.66-1.77 (m, 2H), 1.44-1.61 (m, 4H), 1.16-1.34 (m, 2H); MS (ESI) *m/z* 270/272 ([M+H]⁺, 98%/100%).

25

6-Bromo-spiro[4H-3, 1'-cyclohexane-2-(1H)-one] was prepared from 1-(2-amino-5-bromo-phenyl) cyclohexanol and carbonyl diimidazole according to the procedure of Example 2. The product was obtained as an off-white solid: mp 208-210 °C; ¹H-NMR (DMSO-_d₆) δ 10.26 (s, 1H), 7.45 (d, 1H, *J* = 2.2 Hz), 7.39 (dd, 1H, *J* = 8.2, 2.2 Hz), 6.81 (d, 1H, *J* = 8.3 Hz), 1.90-1.97 (m, 2H), 1.80-1.85 (m, 5H), 1.25-1.35 (m, 1H); MS (APCI) *m/z* 296 ([M+H]⁺, 68%).

30

Spiro-(4, 1'-cyclohexane-1, 4-dihydro-2-oxo-2H-3, 1-benzoxazin-6-yl) boronic acid, prepared according to the procedure of Example 4 using 6-bromo-spiro[4H-3, 1-benzoxazine-4, 1'-cyclohexane-2-(1H)-one, as an off-white solid: mp 223-225 °C.

¹H-NMR (DMSO-d₆) δ 10.17 (s, 1H, D₂O exchangeable), 7.92 (s, 2H, D₂O exchangeable), 7.67 (s, 1H), 7.63 (dd, 1H, *J* = 8.0, 1.1 Hz), 6.81 (d, 1H, *J* = 7.9 Hz), 1.96(s, 1H), 1.93 (s, 1H), 1.57-1.88 (m, 7H), 1.24-1.34 (m, 1H); MS (ESI) *m/z* 262 (M+H)⁺.

4-(1, 2-Dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-2-thiophenecarbonitrile was prepared, according to the procedure of Example 5 from spiro-(4, 1'-cyclohexane-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 3-bromo-5-cyanothiophene, as white crystals: mp 230-232 °C; IR (KBr) 2200 cm⁻¹; ¹H-NMR (DMSO-d₆) δ 10.29 (s, 1H), 8.49 (s, 1H), 8.33 (s, 1H), 7.69-7.63 (m, 2H), 6.93-6.91 (d, 1H, *J* = 8.2 Hz), 1.99-1.87 (m, 4H), 1.73-1.64 (m, 5H), 1.38-1.31 (m, 1H); MS(+)APCI *m/z* 325 (M+H)⁺; Anal. Calc. For C₁₈H₁₆N₂O₂S1/4H₂O: C, 65.73; H, 5.06; N, 8.52. Found: C, 65.55; H, 5.06; N, 8.22.

The title compound was prepared, according to the procedure of Example 16 using 4-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-2-thiophenecarbonitrile, as a yellow solid: mp 225-227°C; ¹H-NMR (CDCl₃) δ 8.98 (s, 1H), 7.83 (d, 1H, *J* = 1.47 Hz), 7.63 (d, 1H, *J* = 1.47 Hz), 7.46 (dd, 1H, *J* = 8.2, 1.91 Hz), 7.32 (m, 1H), 6.86 (d, 1H, *J* = 8.19 Hz), 2.28-2.29 (m, 2H), 2.06-2.01 (m, 2H), 1.83-1.70 (m, 5H), 1.37-1.3 (m, 1H); MS (ES) *m/z* 339 ([M-H]⁻).

EXAMPLE 25

5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxaz-6-yl)-2-fluorobenzonitrile

3-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-fluorobenzonitrile was prepared, from (1, 4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 5-bromo-2-fluorobenzonitrile according to the procedure of Example 5, as a white solid: mp 229-230°C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 8.15 (dd, 1H, *J* = 7.39, 2.12 Hz), 7.95-7.89 (m, 1H), 7.59-7.48 (m, 3H), 6.99 (d, 1H, *J* = 8.1 Hz), 1.7 (s, 6H); MS (APCI) *m/z* 297 ([M + H]⁺, 100%); Anal. Calc. For C₁₇H₁₃FN₂O₂: C, 68.91, H, 4.42, N, 9.45. Found: C, 68.74, H, 4.83, N, 9.10.

The title compound was prepared, according to the procedure of Example 16 using 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-2-fluorobenzonitrile, as a white solid: mp 258-259°C; ¹H-NMR (DMSO-d₆) δ 12.3 (s, 1H), 8.35-8.32 (m, 1H), 8.15-8.10 (m, 1H), 7.72-7.7 (m, 2H), 7.66-7.60 (m, 1H), 7.13 (d, 1H, J = 8.07 Hz), 1.7 (s, 6H); LC/MS (ES) m/z 311 ([M + H]⁺, 100%); Anal. Calcd. For C₁₇H₁₃FN₂OS: C, 64.99, H, 4.24, N, 8.66. Found: C, 64.7, H, 4.09, N, 8.66.

EXAMPLE 26

6-(5-Bromopyridin-3-yl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

10 6-(5-Bromo-pyridin-3-yl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, prepared from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 3,5-dibromopyridine according to the procedure of Example 6, as a white solid: mp 211-212°C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 8.92 (d, 1H, J = 1.9 Hz), 8.66 (d, 1H, J = 2.09 Hz), 8.40 (t, 1H, J = 2.02 Hz), 7.72-7.68 (m, 2H), 6.99 (d, 1H, J = 8.1 Hz), 1.7 (s, 6H); MS (APCI) m/z 333([M + H]⁺, 100%), 335([M + H]⁺, 100%); Anal. Calcd. For C₁₅H₁₃BrN₂O₂: C, 54.07, H, 3.93, N, 8.41. Found: C, 54.15, H, 3.89, N, 8.31.

The title compound was prepared, according to the procedure of Example 16 using 6-(5-bromo-pyridin-3-yl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 20 as a white solid: mp 252-253°C; ¹H-NMR (DMSO-d₆) δ 12.3 (s, 1H), 8.94 (s, 1H), 8.69 (s, 1H), 8.44 (s, 1H), 7.78-7.76 (m, 2H), 7.14 (d, 1H, J = 8.8 Hz), 1.7 (s, 6H); LC/MS (ES) m/z 347/349 ([M - H]⁻); Anal. Calcd. For C₁₅H₁₃BrN₂O₂: C, 51.32, H, 3.79, N, 7.98 Found: C, 50.95, H, 3.56, N, 7.72

EXAMPLE 27

6-(3-Chloro-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

25 6-(3-Chloro-5-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1-bromo-3-chloro-5-fluorobenzene according to the procedure of 30 Example 5, as a white solid: mp 193-194 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H),

7.67-7.64 (m, 3H), 7.61-7.57 (m, 1H), 7.41-7.37 (m, 1H), 6.96 (d, 1H, $J = 8.72$ Hz), 1.7 (s, 6H); MS (APCI) m/z 306 ($[M + H]^+$, 100%); Anal. Calc. For $C_{16}H_{13}ClFNO_2$: C, 62.86, H, 4.29, N, 4.58. Found: C, 62.98, H, 4.1, N, 4.6.

The title compound was prepared, according to the procedure of Example 16, starting with 6-(3-chloro-5-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one: mp 204-205°C; 1H -NMR ($CDCl_3$) δ 10.0 (s, 1H), 7.49 (m, 1H), 7.31 (bs, 2H), 7.15-7.08 (m, 2H), 7.01 (d, 1H, $J = 8.23$ Hz), 1.9 (s, 6H); LC/MS (ES) m/z 320/322 ($[M - H]^+$).

10

EXAMPLE 28**6-(3-Bromo-5-methylphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione**

6-(3-Bromo-5-methyl-phenyl)-4,4-dimethyl-1,4-dihydrobenzo-[d][1,3]oxazin-2-one was prepared, using (4,4-dimethyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 3,5-dibromotoluene according to the procedure of Example 5, as a white solid: mp 231-233 °C; 1H -NMR ($DMSO-d_6$) δ 10.4 (s, 1H), 7.66 (s, 1H), 7.58-7.56 (m, 2H), 7.50 (s, 1H), 7.37 (s, 1H), 6.95 (d, 1H, $J = 8.67$ Hz), 2.37 (s, 3H), 1.67 (s, 6H); MS (ESI) m/z 344/346 ($[M - H]^+$, 100%); Anal. Calc. For $C_{17}H_{16}BrNO_2$: C, 58.98, H, 4.66, N, 4.05. Found: C, 58.82, H, 4.62, N, 3.94.

20

The title compound was prepared according to the procedure of Example 16, using 6-(3-Bromo-5-methyl-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a yellow solid: mp 183-184°C; 1H -NMR ($CDCl_3$) δ 9.8 (s, 1H), 7.48-7.46 (m, 2H), 7.34-7.25 (m, 4H), 6.97 (d, 1H, $J = 8.2$ Hz), 2.4 (s, 3H), 1.8 (s, 6H); MS (ES) m/z 360/362 ($[M - H]^+$).

25

EXAMPLE 29**6-(3-Bromo-5-trifluoromethoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione**

6-(3-Bromo-5-trifluoromethoxy-phenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]-oxazin-2-one was prepared, using (4, 4-dimethyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 1, 3-dibromo-5-

30

trifluoromethoxybenzene according to the procedure of Example 5, as a white solid: mp 214-216 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.99 (s, 1H), 7.73 (s, 1H), 7.68-7.62 (m, 3H), 6.97 (d, 1H, *J* = 8.0 Hz), 1.68 (s, 6H); MS (ESI) *m/z* 414 ([M - H]⁺, 100%); Anal. Calc. For C₁₇H₁₃BrF₃NO₃: C, 49.06, H, 3.15, N, 3.37. Found: C, 49.16, H, 3.05, N, 3.30.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3-Bromo-5-trifluoromethoxy-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a yellow solid: mp 192-193°C; ¹H-NMR (CDCl₃) δ 9.4 (s, 1H), 7.61 (s, 1H), 7.49-7.46 (m, 1H), 7.40 (s, 1H), 7.30 (s, 2H), 6.96 (d, 1H, *J* = 8.22 Hz) 1.9 (s, 6H); MS (ES) *m/z* 431/433 ([M - H]⁺).

EXAMPLE 30

3-(1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-5-fluorobenzonitrile

3-(1, 2-Dihydro-2-oxospiro[4H-3, 1-benzoxazine-4, 1-cyclohexan]-6-yl)-5-fluorobenzonitrile was prepared, according to the procedure of Example 5 from spiro-(4, 1'-cyclohexane-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 3-bromo-5-fluorobenzonitrile, as a white powder: mp 250-253 °C; IR (KBr) 2220 cm⁻¹; ¹H-NMR (DMSO-d₆) δ 10.34 (s, 1H), 8.13 (s, 1H), 8.0 (d, 1H, *J* = 10.6 Hz), 7.80-7.7 (m, 3 H), 6.98-6.95 (d, 1H, *J* = 8.1 Hz), 1.99-1.97 (m, 4H), 1.76-1.65 (m, 6H), 1.37-1.33 (m, 1H). MS (EI) *m/z* 336 (M⁺); Anal. Calc. For C₂₀H₁₇FN₂O₂H₂O: C, 67.78; H, 5.40; N, 7.90. Found: C, 67.9; H, 4.93; N, 7.67.

The title compound was prepared, according to the procedure of Example 16 using 3-(1,2-Dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-5-fluorobenzonitrile: mp 235-237°C; ¹H-NMR (CDCl₃) δ 10.0 (s, 1H), 7.76-7.69 (m, 2H), 7.50-7.33 (m, 3H), 7.03 (d, 1H, *J* = 8.8 Hz), 2.3-1.26 (m, 10H); MS (ES) *m/z* 351 ([M - H]⁺).

EXAMPLE 31

3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methylbenzonitrile

3-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-methylbenzonitrile was prepared, from (4, 4-dimethyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 3-bromo-5-methylbenzonitrile according to the procedure of Example 5, as a white solid: mp 256-258 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H),
5 7.99 (s, 1H), 7.86 (s, 1H), 7.67-7.62 (m, 3H), 6.97 (d, 1H, *J* = 8.11 Hz), 2.42 (s, 3H), 1.68 (s, 6H); MS (APCI) *m/z* 293 ([M+H]⁺, 100%); Anal. Calc. For C₁₈H₁₆N₂O₂: C, 73.96, H, 5.52, N, 9.58. Found: C, 73.26, H, 5.46, N, 9.24.

The title compound was prepared, according to the procedure for Example 16 starting with 6-(3-cyano-5-methyl-phenyl)-4,4-dimethyl-1,4-dihydro-
10 benzo[d][1,3]oxazin-2-one: mp 230-231 °C; ¹H-NMR (CDCl₃) δ 9.1 (s, 1H), 7.61 (s, 1H), 7.55 (s, 1H), 7.50-7.47 (m, 2H), 7.32-7.31 (m, 1H), 6.91 (d, 1H, *J* = 8.2), 2.5 (s, 3H), 1.8 (s, 6H); MS (ES) *m/z* 307 ([M- H]⁻).

EXAMPLE 32

15 6-(3,5-Dichlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
6-(3,5-dichloro-phenyl)-4,4-dimethyl-1,4-dihydrobenzo-[d][1,3]oxazin-2-one was prepared, from 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one and 3,5-dichlorophenyl boronic acid according to the procedure of Example 4, as a white solid: mp 245-246 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.77 (m, 2H), 7.67-7.64
20 (m, 2H), 7.56 (bs, 1H), 6.96 (d, 1H, *J* = 7.98 Hz), 1.7 (s, 6H); MS (EI) *m/z* 321 ([M+H]⁺, 40%); Anal. Calc. For C₁₆H₁₃Cl₂NO₂: C, 59.32, H, 4.11, N, 4.32. Found: C, 59.13, H, 4.29, N, 4.17.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3,5-Dichloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-
25 2-one: mp 206-208 °C; ¹H-NMR (CDCl₃) δ 9.5 (s, 1H), 7.49-7.45 (m, 1H), 7.40-7.36 (m, 3H), 7.3-7.29 (m, 1H), 6.95 (d, 1H, *J* = 8.23), 1.8 (s, 6H); MS (ES) *m/z* 336/338 ([M- H]⁻).

EXAMPLE 33

WAY-164904: 5-(4,4-Dimethyl-1,2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)isophthalonitrile

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-
isophthalonitrile was prepared from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-
benzoxin-6-yl)boronic acid and 5-bromoisophthalonitrile according to the procedure
Example 5, as a white solid: mp 288-289 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H),
8.58 (s, 2H), 8.40 (d, 1H, J = 0.77 Hz), 7.80-7.75 (m, 2H), 6.99 (d, 1H, J = 8.2 Hz),
1.7 (s, 6H); MS (EI) m/z 303([M⁺], 20%); Anal. Calc. For C₁₈H₁₃N₃O₂·1.65 H₂O: C,
64.92, H, 4.93, N, 12.62. Found: C, 64.74, H, 4.69, N, 12.32.

The title compound was prepared according to the procedure of Example 16
starting with 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-
isophthalonitrile: mp 240-242°C; ¹H-NMR (CDCl₃) δ 9.4 (s, 1H), 8.03 (d, 2H, J =
1.25 Hz), 7.92 (s, 1H), 7.50 (dd, 1H, J = 8.22, 1.89 Hz), 7.33 (d, 1H, J = 1.8 Hz),
7.01 (d, 1H, J = 8.24 Hz), 1.84 (s, 6H); MS (ES) m/z 318 ([M-H]⁻).

EXAMPLE 34

5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-furan-2-
carbonitrile was prepared, according to the procedure of Example 5 from 2-bromo-5-
cyanofuran (1.0 g, 5.6 mmol) (J. Med. Chem. (1997), 40(23), 3804-3819) and (1,4-
dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid (1.8 g, 8.18 mmol),
as a white solid (0.39 g, 1.45 mmol, 17%): mp 257 - 260 °C; ¹H-NMR (DMSO-d₆) δ
10.48 (s, 1H), 7.73 - 7.70 (m, 3H), 7.19 (d, 1 H, J = 3.8 Hz), 6.98 (d, 1 H, J = 8.9
Hz), 1.66 (s, 6H); MS ((+)-APCI) m/z = 269 (M+H)⁺.

The title compound was prepared according to the procedure of Example 16
using 5-(1,4-Dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-
furancarbonitrile: mp 200°C decomposes; ¹H-NMR (CDCl₃) δ 9.1 (s, 1H), 7.63 (dd,
1H, J = 8.26, 1.68 Hz), 7.53 (d, 1H, J = 1.59 Hz), 7.19 (d, 1H, J = 3.7 Hz), 6.89 (d,
1H, J = 8.31 Hz), 6.71 (d, 1H, J = 3.72 Hz), 1.8 (s, 6H); MS (ES) m/z 283 ([M-H]⁻)

EXAMPLE 35

4,4-Diethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione

4,4-Diethyl-6-(3-nitrophenyl)-1,4-dihydrobenzo[d][1,3]oxazin-2-one was prepared, from 4,4-diethyl-6-iodo-1,4-dihydrobenzo[d][1,3]oxazin-2-one and 3-nitrophenyl boronic acid according to the procedure of Example 4, as an off-white solid: mp 193-194 °C; ¹H-NMR (CDCl₃) δ 9.19 (s, 1H, D₂O exchangeable), 8.38 (t, 1H, *J* = 1.9 Hz), 8.20 (m, 1H), 7.83 (m, 1H), 7.61 (t, 1H, *J* = 8.0 Hz), 7.50 (dd, 1H, *J* = 8.2, 2.0 Hz), 7.23 (d, 1H, *J* = 1.7 Hz), 6.99 (d, 1H, *J* = 8.3 Hz), 2.09 (q, 4H, *J* = 7.4 Hz), 0.96 (t, 6H, *J* = 8.3 Hz); MS (EI) *m/z* 325 ([M-H]⁺, 100%). Anal. Calc. For C₁₈H₁₈N₂O₄·0.3 H₂O: C, 65.17, H, 5.65, N, 8.44. Found: C, 65.31, H, 5.60, N, 8.10.

The title compound was prepared, according to the procedure of Example 16 starting with 4,4-Diethyl-6-(3-nitro-phenyl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a yellow solid: mp 180-181°C; ¹H-NMR (CDCl₃) δ 9.1 (s, 1H), 8.38 (t, 1H, *J* = 1.94 Hz), 8.25-8.22 (m, 1H), 7.87-7.85 (m, 1H), 7.64 (t, 1H, *J* = 7.99 Hz), 7.55 (dd, 1H, *J* = 8.24, 1.89 Hz), 7.25 (d, 1H, *J* = 1.71 Hz), 6.93 (d, 1H, *J* = 8.25 Hz), 2.2-2.03 (m, 4H), 0.96 (t, 6H, *J* = 7.33 Hz); MS (ES) *m/z* 341 ([M-H]⁺).

EXAMPLE 36

6-(3-Chlorophenyl)-4-methyl-4-phenyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

A mixture of 2-amino-5-bromo-*N*-methoxy-*N*-methylbenzamide (7.78g, 30 mmol), 3-chlorophenyl boronic acid (5.63g, 36 mmol), tetrakis(triphenylphosphine)palladium (0) (1.73g, 1.5 mmol), and sodium carbonate (7.63g, 72 mmol) in a mixture of DME and water (150 mL/30 mL) was degassed to remove the oxygen and heated at 85°C under nitrogen for 3 hours. The reaction mixture was cooled to room temperature and treated with brine (30 mL) and ethyl acetate (100 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x40 mL). The combined organic layers were washed with brine and dried with MgSO₄. After removal of the solvent, the residue was purified by a flash chromatography (silica gel, hexane:ethyl acetate/1:1) to give 5-(3-chlorophenyl)-*N*-methoxy-*N*-methylbenzamide as a brown oil (5g, 57%). To a solution of this benzamide (5g, 17.2 mmol) in anhydrous THF was added in a

dropwise fashion a solution of methyllithium in ether (1.4M, 28.6 mL, 40 mL) at -78 °C under nitrogen. After stirring for 30 minutes, the reaction mixture was treated with a saturated aqueous ammonium chloride solution (50 mL) at -78 °C. Ethyl acetate (100 mL) was added, organic layer was separated, and aqueous layer was extracted with ethyl acetate (3x20 mL). The combined organic layers were washed (brine) and dried (MgSO₄). After removal of the solvent, the residue was purified by a flash chromatography (silica gel, hexane:ethyl acetate/2:1) to afford 1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone as a yellow solid (2g, 47%): mp 89-90 °C; ¹H-NMR (CDCl₃) δ 7.89 (d, 1H, *J* = 2.0 Hz), 7.51 (m, 2H), 7.25-7.40 (m, 3H), 6.73 (d, 1H, *J* = 8.6 Hz), 6.38 (br, 2H), 2.65 (s, 3H); MS (EI) *m/z* 268([M+Na]⁺, 60%); Anal. Calc. For C₁₄H₁₂ClNO: C, 68.44, H, 4.92, N, 5.70. Found: C, 68.40, H, 4.89, N, 5.61.

6-(3-Chlorophenyl)-4-methyl-4-phenyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, from 1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone (0.2g, 0.82 mmol) and phenylmagnesium bromide followed by treatment with CDI in THF, as a white solid: mp 179-180 °C; ¹H-NMR (CDCl₃) δ 8.27 (s, 1H, D₂O exchangeable), 7.51-7.57 (m, 2H), 7.28-7.45 (m, 9H), 6.92 (d, 1H, *J* = 8.4 Hz), 2.12 (s, 3H); MS (ESI) *m/z* 348 ([M-H]⁻, 100%); Anal. Calc. For C₂₁H₁₆ClNO₂: C, 72.10, H, 4.61, N, 4.00. Found: C, 71.72, H, 4.86, N, 3.91.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3-chlorophenyl)-4-methyl-4-phenyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 202-203°C; ¹H-NMR (CDCl₃) δ 8.9 (s, 1H), 7.59-7.56 (m, 2H), 7.49-7.30 (m, 9H), 6.91 (d, 1H, *J* = 8.19 Hz), 2.2 (s, 3H); MS (ES) *m/z* 364 ([M-H]⁻).

EXAMPLE 37

4-Allyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

To a solution of 1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone (0.2g, 0.82 mmol) in anhydrous THF (10 mL) was added a solution of allylmagnesium bromide in ether (1.0 M, 3 mL, 3 mmol) at 0°C under nitrogen. The reaction solution was slowly warmed to ambient temperature and stirred under nitrogen for 1 hour. A saturated aqueous ammonium chloride solution (10 mL) was added and was followed by

addition of ethyl acetate (50 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine and dried with MgSO_4 . After removal of solvent, the residue was purified by a flash chromatography (silica gel, hexane:ethyl acetate/3:1) to afford an amino carbinol intermediate which was used in next step without further purification.

To a solution of the above amino carbinol in anhydrous THF was added CDI (0.38g, 2.3 mmol) at ambient temperature under nitrogen. The reaction solution was heated at 55 °C for 12 hours and then cooled to room temperature. The solvent was removed *in vacuo* and the residue was purified by a flash chromatography (silica gel, hexane:ethyl acetate/2:1) to yield 4-allyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one as a white solid (130 mg, 52%): mp 128-129 °C; $^1\text{H-NMR}$ (CDCl_3) δ 8.68 (s, 1H, D_2O exchangeable), 7.50 (s, 1H), 7.44 (dd, 1H, $J = 8.2, 1.9$ Hz), 7.31-7.40 (m, 3H), 7.25 (d, 1H, $J = 1.6$ Hz), 6.92 (d, 1H, $J = 8.2$ Hz), 5.70-5.85 (m, 1H), 5.17 (m, 2H), 2.76 (m, 2H), 1.79 (s, 3H); MS (ESI) m/z 314 ($[\text{M}+\text{H}]^+$, 40%); Anal. Calc. For $\text{C}_{18}\text{H}_{16}\text{ClNO}_2$: C, 68.90, H, 5.14, N, 4.46. Found: C, 68.90, H, 5.18, N, 4.43.

The title compound was prepared according to the procedure of Example 16 starting with 4-Allyl-6-(3-chloro-phenyl)-4-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one: mp 150-151 °C; $^1\text{H-NMR}$ (CDCl_3) δ 8.9 (s, 1H), 7.50-7.47 (m, 2H), 7.40-7.35 (m, 3H), 7.27 (s, 1H), 6.87 (d, 1H, $J = 8.22$ Hz), 5.81-5.72 (m, 1H), 5.19-5.13 (m, 2H), 2.78-2.75 (m, 2H), 1.82 (s, 3H); MS (ES) m/z 328 ($[\text{M}-\text{H}]^-$).

EXAMPLE 38

3-Chloro-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile

3-Chloro-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-
5 benzonitrile was prepared, from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1-bromo-3-chlorobenzonitrile according to the procedure of Example 5, as a white solid: mp 256-257 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 8.22 (bs, 1H), 8.15 (bs, 1H), 7.98 (bs, 1H), 7.74-7.71 (m, 2H), 6.97 (d, 1H, *J* = 8.09 Hz), 1.7 (s, 6H); MS (ESI) *m/z* 311 ([M - H]⁻, 100%); Anal. Calc. For C₁₇H₁₃ClN₂O₂:
10 C, 65.29, H, 4.19, N, 8.96. Found: C, 65.25, H, 3.92, N, 8.71.

The title compound was prepared according to the procedure of Example 16 starting with 3-chloro-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile: mp 249-251 °C; ¹H-NMR (CDCl₃) δ 9.7 (s, 1H), 7.74-7.73 (m, 1H), 7.71-7.70 (m, 1H), 7.64-7.63 (m, 1H), 7.48 (dd, 1H, *J* = 8.24, 1.86 Hz), 7.3 (d, 1H, *J* = 1.73 Hz), 7.01 (d, 1H, *J* = 8.24 Hz), 1.8 (s, 6H); MS (ES) *m/z* 327/329 ([M - H]⁻).
15

EXAMPLE 39

6-(3,5-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3,5-difluoro-phenyl)-4,4-dimethyl-1,4-dihydrobenzo-[d][1,3]oxazin-2-one
20 was prepared, according to the procedure of Example 5 from (4,4-dimethyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 1-bromo-3,5-difluorobenzene, as a white solid: mp 218-219 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.67-7.65 (m, 2H), 7.49 (d, 2H, *J* = 7.73 Hz), 7.19 (t, 1H, *J* = 9.29 Hz), 6.96 (d, 1H, *J* = 8.88 Hz), 1.7 (s, 6H); MS (APCI) *m/z* 290 ([M + H]⁺, 100%); Anal. Calc. For
25 C₁₆H₁₃F₂N₂O₂: C, 66.43, H, 4.53, N, 4.84. Found: C, 66.01, H, 4.46, N, 4.67.

The title compound was prepared according to the procedure of Example 16 starting with 6-(3,5-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one: mp 224-225 °C; ¹H-NMR (CDCl₃) δ 9.7 (s, 1H), 7.48 (dd, 1H, *J* = 8.16, 1.74 Hz), 7.31 (d, 1H, *J* = 1.66 Hz), 7.08-7.03 (m, 2H), 6.98 (d, 1H, *J* = 8.23 Hz), 6.85-
30 6.78 (m, 1H), 1.8 (s, 6H); MS (ES) *m/z* 304 ([M - H]⁻).

EXAMPLE 40

6-(3-Fluoro-5-methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

5 6-(3-Fluoro-5-methoxy-phenyl)-4,4-dimethyl-1,4-dihydro-
benzo[d][1,3]oxazin-2-one was prepared, from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-
3,1-benzoxin-6-yl)boronic acid and 3-bromo-5-fluoroanisole according to the
procedure of Example 5, as a white solid: mp 181-182 °C; ¹H-NMR (DMSO-d₆) δ
10.4 (s, 1H), 7.62-7.59 (m, 2H), 7.13-7.06 (m, 2H), 6.97-6.94 (d, 1H, *J* = 8.89 Hz),
10 6.80 (dt, 1H, *J* = 10.95, 2.12 Hz), 3.8 (s, 3H), 1.7 (s, 6H); MS (ESI) *m/z* 302 ([M +
H]⁺, 100%); Anal. Calc. For C₁₇H₁₆FN₂O₃·0.1 H₂O: C, 67.36, H, 5.39, N, 4.62.
Found: C, 67.11, H, 5.44, N, 4.48.

The title compound was prepared, according to the procedure of Example 16
starting with 6-(3-fluoro-5-methoxy-phenyl)-4,4-dimethyl-1,4-dihydro-
15 benzo[d][1,3]oxazin-2-one, as a white solid: mp 170-171°C; ¹H-NMR (CDCl₃) δ 9.2
(s, 1H), 7.48 (dd, 1H, *J* = 8.18, 1.84 Hz), 7.32 (d, 1H, *J* = 1.66 Hz), 6.91 (d, 1H, *J* =
8.23 Hz), 6.84 (d, 1H, *J* = 2.11 Hz), 6.82-6.81 (m, 1H), 6.66-6.61 (m, 1H), 3.9 (s,
3H), 1.8 (s, 6H); MS (ES) *m/z* 316 ([M- H]⁻).

20

EXAMPLE 41

3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methoxybenzonitrile

A mixture of (4,4-dimethyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)boronic
acid (4.2 g, 19.0 mmol), 3-cyano-5-methoxybenzyltriflate (5.1 g, 19.0 mmol),
25 tetrakis(triphenylphosphine)-palladium (0) (1.1 g, 0.95 mmol), sodium carbonate (4.0
g, 38.0 mmol), lithium bromide (5 g, 57 mmol) in DME (50 mL), and water (25 mL)
under a blanket of nitrogen, was stirred for 15 minutes at 50 °C. This solution was
then was heated at 85 °C for 1 hour. The reaction mixture was cooled to room
temperature and ethyl acetate (100 mL) was added. The organic layers were washed
30 twice with aqueous ammonium chloride (100 mL) and once with brine (100 mL), dried
over magnesium sulfate and concentrated. Purification via chromatography (silica gel,

40% ethyl acetate/ hexane) gave 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-methoxy-benzonitrile as a white solid (0.69 g, 53%): mp 254-255 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.84 (s, 1H), 7.67-7.61 (m, 2H), 7.55 (bs, 1H), 7.4 (bs 1H) 6.99 (d, 1H, *J* = 7.94 Hz), 3.88 (s, 3H), 1.67 (s, 6H,); MS (EI) *m/z* 308 ([M + H]⁺, 30%); Anal. Calc. For C₁₈H₁₆N₂O₃: C, 68.13, H, 5.40, N, 8.83. Found: C, 68.03, H, 5.22, N, 8.46.

The title compound was prepared, according to the procedure of Example 16 starting with 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-methoxy-benzonitrile, as an off-white solid: mp 201-202°C; ¹H-NMR (CDCl₃) δ 9.1 (s, 1H), 7.48 (dd, 1H, *J* = 8.16, 1.8 Hz), 7.41 (s, 1H), 7.31 (d, 1H, *J* = 1.69 Hz), 7.27 (m, 1H), 7.14 (m, 1H), 6.92 (d, 1H, *J* = 8.2 Hz), 3.9 (s, 3H), 1.8 (s, 6H); MS (ES) *m/z* 323 ([M - H]⁻).

EXAMPLE 42

15 6-(3-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3-Fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, from 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 1-bromo-3-fluorobenzene according to the procedure of Example 4, as a light yellow solid: mp 181-182 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.62-7.44 (m, 5H), 7.16 (t, 1H, *J* = 2.22 Hz), 6.97 (d, 1H, *J* = 8.83), 1.67 (s, 6H); MS (EI) *m/z* 271 ([M + H]⁺, 40%); Anal. Calc. For C₁₆H₁₄FNO₂: C, 69.91, H, 5.3, N, 5.1. Found: C, 70.0, H, 5.32, N, 4.92.

The title compound was prepared, according to the procedure of Example 16 using 6-(3-Fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 194-195°C; ¹H-NMR (CDCl₃) δ 8.9 (s, 1H), 7.50 (dd, 1H, *J* = 8.15, 1.73 Hz), 7.46-7.38 (m, 1H), 7.34-7.30 (m, 2H), 7.25-7.21 (m, 1H), 7.10-7.04 (m, 1H), 6.89 (d, 1H, *J* = 8.21 Hz), 1.8 (s, 6H); MS (ES) *m/z* 286 ([M - H]⁻).

EXAMPLE 43

30 6-[3-Fluoro-5-(trifluoromethyl)phenyl]-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3-Fluoro-5-trifluoromethyl-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1-bromo-3-fluoro-5-trifluoromethylbenzene according to the procedure of Example 5, as a white solid: mp 207-208 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.94-7.9 (m, 2H), 7.73-7.7 (m, 2H), 7.63 (d, 1H, J = 8.58 Hz), 6.99 (d, 1H, J = 8.68 Hz), 1.7 (s, 6H); MS (EI) m/z 339([M⁺], 60%); Anal. Calc. For C₁₇H₁₃F₄NO₂: C, 60.18, H, 3.86, N, 4.13. Found: C, 59.9, H, 3.99, N, 4.06.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3-fluoro-5-trifluoromethyl-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 204-206 °C; ¹H-NMR (CDCl₃) δ 9.2 (s, 1H), 7.56 (s, 1H), 7.5 (dd, 1H, J = 8.14, 1.97 Hz), 7.44-7.38 (m, 1H), 7.36-7.30 (m, 2H), 6.92 (d, 1H, J = 8.14 Hz), 1.83 (s, 6H); MS (ES) m/z 354 ([M- H]).

EXAMPLE 44

15 6-(2-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(2-Fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, according to the procedure of Example 5 from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1-bromo-2-fluorobenzene, as off-white crystals: mp 164-165 °C; ¹H-NMR(DMSO-d₆) δ 10.33 (s, 1H), 7.56 (m, 1H), 7.25-7.45 (m, 4H), 6.98 (d, 1H, J = 8.7 Hz), 1.64 (s, 6H).

The title compound was prepared, according to the procedure of Example 16 starting with 6-(2-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 171-173 °C; ¹H-NMR (CDCl₃) δ 8.97 (s, 1H), 7.5-7.13 (m, 6H), 6.88 (d, 1H, J = 8.14 Hz), 1.80 (s, 6H); MS (ES) m/z 286 ([M- H]).

25

EXAMPLE 45

6-(3,4-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3,4-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, according to the procedure of Example 5 from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1-bromo-3, 4-difluorobenzene,

30

as off-white crystals: mp 207-208 °C; ¹H-NMR(DMSO-d₆) δ 10.35 (s, 1H), 7.79 (m, 1H), 7.40-7.63 (m, 4H), 6.95 (d, 1H, *J* = 8.9 Hz), 1.62 (s, 6H).

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3,4-difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a yellow solid: mp 209-211 °C; ¹H-NMR (CDCl₃) δ 8.94 (s, 1H), 7.44 (dd, 1H, *J* = 8.35, 1.98 Hz), 7.36-7.22 (m, 4H), 6.87 (d, 1H, *J* = 8.35 Hz), 1.81 (s, 6H); MS (ES) *m/z* 304 ([M- H]⁺).

EXAMPLE 46

10 6-(4-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(4-Fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, according to the procedure of Example 5 from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1-bromo-4-fluorobenzene, as off-white crystals: mp 232-233 °C; ¹H-NMR (DMSO-d₆) δ 10.3 (s, 1H), 7.74 (m, 2H), 7.53 (m, 15 2H), 7.28 (m, 2H), 6.96 (d, 1H, *J* = 8.9 Hz), 1.63 (s, 6H).

The title compound was prepared, according to the procedure of Example 16 starting with 6-(4-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 221-223 °C; ¹H-NMR (CDCl₃) δ 8.98 (s, 1H), 7.5-7.44 (m, 3H), 7.5 (m, 1H), 7.17-7.10 (m, 2H), 6.87 (d, 1H, *J* = 8.14 Hz), 1.81 (s, 6H); MS (ES) *m/z* 20 286 ([M- H]⁺).

EXAMPLE 47

3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-fluorobenzonitrile

25 3-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-fluorobenzonitrile was prepared, from (1, 4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 5-bromo-2-fluorobenzonitrile according to the procedure of Example 5, as a white solid: mp 229-230 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 8.15 (dd, 1H, *J* = 7.39, 2.12 Hz), 7.95-7.89 (m, 1H), 7.59-7.48 (m, 3H), 6.99 (d, 1H, *J* = 8.1 Hz), 1.7 (s, 6H); MS (APCI) *m/z* 297 ([M + H]⁺, 100%); Anal. Calc. For 30 C₁₇H₁₃FN₂O₂: C, 68.91, H, 4.42, N, 9.45. Found: C, 68.74, H, 4.83, N, 9.10.

The title compound was prepared, according to the procedure of Example 16 starting with 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-fluorobenzonitrile, as a yellow solid: mp 250-251°C; ¹H-NMR (CDCl₃) δ 8.83 (s, 1H), 7.73 (dd, 1H, *J* = 8.34, 2.19 Hz), 7.68-7.64 (m, 1H), 7.48-7.44 (m, 1H), 7.32-7.28 (m, 2H), 6.9 (d, 1H, *J* = 8.34 Hz), 1.81 (s, 6H); MS (ES) *m/z* 311 ([M- H]⁻).

EXAMPLE 48

6-(2,3-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(2,3-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, according to the procedure of Example 5 from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 2,3-difluorobenzyltriflate, as a yellow solid: mp 166-167 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.5-7.2 (m, 5H), 7.0 (m, 1H), 1.7 (s, 6H); MS (EI) *m/z* 289 ([M+H]⁺); Anal. Calc. For C₁₆H₁₃F₂NO₂: C, 66.43, H, 4.53, N, 4.84. Found: C, 66.15, H, 4.37, N, 4.64.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(2,3-difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 197-198°C; ¹H-NMR (CDCl₃) δ 9.02 (s, 1H), 7.49-7.45 (m, 1H), 7.34 (s, 1H), 7.2-7.13 (m, 3H), 6.9 (d, 1H, *J* = 8.14 Hz), 1.80 (s, 6H); MS (ES) *m/z* 304 ([M- H]⁻).

EXAMPLE 49

3-(8-Bromo-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile

To a mixture of 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile (0.5g, 1.7 mmol) and sodium acetate (0.2g, 2.4 mmol) in acetic acid (5 mL) was added, at room temperature under nitrogen, bromine (0.12 mL, 2.34 mmol). The reaction mixture was stirred for 20 hours and then poured into ice water (30 mL). The precipitate was collected on a filter and washed with water (3x5 mL) to yield 3-(8-bromo-4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile as an off-white solid (0.48g, 75%): mp 216-217 °C; ; ¹H-NMR

(DMSO- d_6) δ 9.78 (s, 1H), 8.18 (t, 1H, J = 1.6 Hz), 8.02-8.08 (m, 2H), 7.81 (m, 1H), 7.75 (d, 1H, J = 1.8 Hz), 1.66 (s, 6H). MS (ESI) m/z 373, 375 [$M - H$].

The title compound was prepared according to the procedure of Example 16 starting with 3-(8-bromo-4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile: mp 219-220°C; $^1\text{H-NMR}$ (CDCl_3) δ 9.05 (s, 1H), 7.70 (d, 1H, J = 1.98 Hz), 7.6 (m, 1H), 7.48-7.44 (m, 1H), 7.4-7.36 (m, 1H), 7.26 (m, 1H), 1.80 (s, 6H); MS (ES) m/z 304 ($[M - H]^+$).

EXAMPLE 50

10 4,4-Dimethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione

4,4-Dimethyl-6-(3-nitrophenyl)-1,4-dihydrobenzo[d][1,3]oxazin-2-one was prepared, from 6-iodo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one and 3-nitrophenyl boronic acid according to the procedure of Example 4, as a yellowish solid: mp 244-245 °C; $^1\text{H-NMR}$ (DMSO- d_6) δ 10.38 (s, 1H, D_2O exchangeable), 8.47 (s, 1H), 8.14-8.20 (m, 2H), 7.70-7.76 (m, 3H), 7.01 (d, 1H, J = 8.1 Hz), 1.68 (s, 6H); MS (EI) m/z 297($[M - H]^+$, 100%); Anal. Calc. For $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_4$: C, 64.42, H, 4.73, N, 9.39. Found: C, 63.93, H, 4.91, N, 8.71.

The title compound was prepared, according to the procedure of Example 16 starting with 4,4-dimethyl-6-(3-nitro-phenyl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a yellow solid: mp 224-226°C; $^1\text{H-NMR}$ (CDCl_3) δ 8.89 (s, 1H), 8.40 (s, 1H), 8.26-8.22 (m, 1H), 7.88-7.86 (m, 1H), 7.64 (t, 1H, J = 7.97 Hz), 7.57 (dd, 1H, J = 8.21, 1.3 Hz), 7.40 (m, 1H), 6.94 (d, 1H, J = 8.22 Hz), 1.80 (s, 6H); MS (ES) m/z 313 ($[M - H]^+$).

25 EXAMPLE 51

6-(3-Chlorophenyl)-4,4-diethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3-Chlorophenyl)-4,4-diethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one was prepared, from 4,4-diethyl-6-iodo-1,4-dihydrobenzo[d][1,3]oxazin-2-one and 3-chlorophenyl boronic acid according to the procedure of Example 4, as a white solid: mp 150-151 °C; $^1\text{H-NMR}$ (CDCl_3) δ 8.52 (s, 1H, D_2O exchangeable), 7.50 (s, 1H), 7.31-7.44 (m, 4H), 7.16 (d, 1H, J = 1.5 Hz), 6.89 (d, 1H, J = 8.2 Hz), 2.03 (m, 4H),

0.94 (t, 6H, $J = 7.4$ Hz); MS (EI) m/z 315 (M^+ , 53%). Anal. Calc. For $C_{18}H_{18}ClNO_2$: C, 68.46, H, 5.75, N, 4.44. Found: C, 68.16, H, 5.81, N, 4.32.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3-chloro-phenyl)-4,4-diethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 148-150°C; 1H -NMR ($CDCl_3$) δ 9.27 (s, 1H), 7.50-7.45 (m, 2H), 7.40-7.34 (m, 3H), 7.17 (d, 1H, $J = 1.64$ Hz), 6.94 (d, 1H, $J = 8.22$ Hz), 2.18-2.01 (m, 4H), 0.94 (t, 6H, $J = 7.33$ Hz); MS (ES) m/z 303/332 ($[M-H]^+$).

EXAMPLE 52

10 6-(3-Methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3-Methoxy-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, according to the procedure of Example 4 from 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one and 3-methoxyphenyl boronic acid, as a yellow solid: mp 164-165 °C; 1H -NMR ($DMSO-d_6$) δ 10.3 (s, 1H), 7.56 (m, 2H), 7.36 (t, 1H, $J = 7.89$ Hz), 7.20 (m, 2H), 6.96 (d, 1H, $J = 8.88$ Hz), 6.91 (dd, 1H, $J = 8.13$, 2.35 Hz), 3.8 (s, 3H), 1.7 (s, 6H); MS (ESI) m/z 284 ($[M+H]^+$, 30%); Anal. Calc. For $C_{17}H_{17}NO_3$: C, 72.07, H, 6.05, N, 4.94. Found: C, 70.58, H, 5.73, N, 4.67.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3-Methoxy-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 142-143°C; 1H -NMR ($CDCl_3$) δ 8.96 (s, 1H), 7.51 (dd, 1H, $J = 8.2$, 1.84 Hz), 7.40-7.35 (m, 2H), 7.13-7.10 (m, 1H), 7.05 (t, 1H, $J = 2.21$ Hz), 6.90 (dd, 1H, $J = 8.09$, 2.46 Hz), 6.87 (d, 1H, $J = 8.2$ Hz), 3.87 (s, 3H), 1.8 (s, 6H); MS (ES) m/z 298 ($[M-H]^+$).

EXAMPLE 53

25 6-(2-Chlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(2-Chloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, according to the procedure of Example 4 from 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one and 2-chlorophenyl boronic acid, as a white solid: mp 181-182 °C; MS (ESI) m/z 288 ($[M+H]^+$, 70%); Anal. Calc. For $C_{16}H_{14}ClNO_2$: C, 66.79, H, 4.90, N, 4.87. Found: C, 66.78, H, 4.82, N, 4.55.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(2-chloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 171-172°C; ¹H-NMR (CDCl₃) δ 8.95 (s, 1H), 7.51-7.47 (m, 1H), 7.40-7.27 (m, 5H), 6.87 (d, 1H, *J* = 8.14 Hz), 1.79 (s, 6H); MS (ES) *m/z* 302/304 ([M- H]⁺).

EXAMPLE 54

4-Benzyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

A mixture of 1-(4-amino-3'-chloro-biphenyl-3-yl)-1-benzyl-ethanol (prepared from 1-(4-amino-3'-chloro-biphenyl-3-yl)-ethanone and benzylmagnesium bromide according to procedure described previously, 0.14 g, 0.42 mmol) and triphosgene (0.04 g, 0.14 mmol) in dry THF (10 mL) was stirred under a blanket of nitrogen for 10 minutes. THF was removed and the residue purified via flash chromatography (silica gel, 35% ethyl acetate/hexane) to give 4-benzyl-6-(3-chloro-phenyl)-4-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (0.045 g, 30%) as an off-white solid: mp 187-188 °C; ¹H-NMR (DMSO-*d*₆) δ 10.1 (s, 1H), 7.70 (t, 1H, *J* = 2.3 Hz), 7.6 (d, 1H, *J* = 8.0 Hz), 7.58-7.53 (m, 2H), 7.46 (t, 1H, *J* = 8.0 Hz), 7.38 (d, 1H, *J* = 8.0 Hz), 7.22-7.17 (m, 3H), 7.06-7.0 (m, 2H), 6.84 (d, 1H, *J* = 9.14 Hz), 3.24 (d, 1H, *J* = 14.3 Hz), 3.06 (d, 1H, *J* = 14.3 Hz), 1.68 (s, 3H); MS (ESI) *m/z* 364 ([M+H]⁺, 100%); Anal. Calc. For C₂₂H₁₈ClNO₂: C, 72.63; H, 4.99; N, 3.85. Found: C, 71.82; H, 5.09; N, 3.58.

The title compound was prepared, according to the procedure of Example 16 starting with 4-benzyl-6-(3-chloro-phenyl)-4-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: ¹H-NMR (CDCl₃) δ 9.09 (s, 1H), 7.63 (dd, 1H, *J* = 8.03, 1.83 Hz), 7.38-7.22 (m, 7H), 7.04-6.97 (m, 3H), 6.83 (d, 1H, *J* = 8.22 Hz), 3.22 (s, 2H), 1.86 (s, 3H); MS (ES) *m/z* 378/380 ([M- H]⁺).

EXAMPLE 55

6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one was prepared, from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-

yl)boronic acid and 1,3-dibromo-5-fluorobenzene following the procedure of Example 5, as a white solid: mp 182-183 °C; ¹H-NMR (DMSO-d₆) δ 10.36 (s, 1H, D₂O exchangeable), 7.78 (s, 1H), 7.58-7.65 (m, 3H), 7.49 (dd, 1H, *J* = 8.3, 1.8 Hz), 6.96 (d, 1H, *J* = 8.5 Hz), 1.69 (s, 6H); ¹⁹F-NMR (DMSO-d₆) □ -112.46 (m, 1F); MS (CI) *m/z* 352 ([M+H]⁺, 78%), 350 ([M+H]⁺, 75%); Anal. Calc. For C₁₆H₁₃BrFNO₂: C, 54.88, H, 3.74, N, 4.00. Found: C, 54.83, H, 3.82, N, 3.95.

The title compound was prepared, according to the procedure of Example 16 starting with 6-(3-bromo-5-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a yellow solid: mp 221-222°C; ¹H-NMR (CDCl₃) δ 9.28 (s, 1H), 7.49-7.45 (m, 2H), 7.30 (d, 1H, *J* = 1.71 Hz), 7.24 (t, 1H, *J* = 2.07 Hz), 7.17 (dt, 1H, *J* = 9.54, 1.99 Hz), 6.93 (d, 1H, *J* = 8.25 Hz), 1.8 (s, 6H); MS (ES) *m/z* 364/366 ([M- H]).

EXAMPLE 56

15 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl) thiophene-2-carbonitrile

5-(4,4-Dimethyl-2-oxo-1, 4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-2-carbonitrile was prepared, according to the procedure of Example 5 using 5-bromo-2-thiophenecarbonitrile and (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid, as an off-white solid: mp 264-266 °C; ¹H-NMR (DMSO-d₆) δ 10.3 (s, 1H), 7.97 (d, 1H, *J* = 7.9 Hz), 7.60-7.66 (m, 3H), 6.96 (d, 1H, *J* = 8.1 Hz), 1.65 (s, 6H); MS (APCI) *m/z* 285 (M+H)⁺, 302 (M+NH₄)⁺. Anal. Calc. For C₁₅H₁₂N₂O₂S: C, 63.36; H, 4.25; N, 9.85. Found: C, 63.01; H, 4.36; N, 9.39.

The title compound was prepared, according to the procedure of Example 16 using 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-2-carbonitrile, as a yellow solid: mp 242-244 °C; ¹H-NMR (CDCl₃) δ 9.05 (s, 1H), 7.61 (d, 1H, *J* = 3.89 Hz), 7.54 (dd, 1H, *J* = 8.23, 1.56 Hz), 7.35 (m, 1H), 7.24 (d, 1H, *J* = 3.89 Hz), 6.88 (d, 1H, *J* = 8.26 Hz), 1.8 (s, 6H); MS (ES) *m/z* 299 ([M- H]).

EXAMPLE 57

3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile

N-(*tert*-Butoxycarbonylamino)-3-fluorobenzoic acid (Takagishi et al. *Synlett* 4, 360-2 (1992); mp 159-161 °C) was deprotected using trifluoroacetic acid to give *o*-amino benzoic acid, which was then treated with methylmagnesium bromide to afford *o*-amino dimethyl carbinol. The *o*-amino dimethyl carbinol (2.23 g, 13.2 mmol) was treated with 1,1'-carbonyldiimidazole (2.8 g, 17.2 mmol) in THF (20 mL) at 50 °C for 12 hours. The solution was then cooled to room temperature and ethyl acetate (100 mL) was added. The organic layer was washed with 10% aqueous HCl solution (2x25 mL), dried over MgSO₄ and concentrated. The residue was purified via chromatography (silica gel, 10% ethyl acetate/hexane) to give 8-fluoro-4,4-dimethyl-dihydro-benzo[d][1,3]oxazin-2-one as a white solid (1.3 g, 50%); mp 127-128 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.22-7.12 (m, 2H), 7.07-7.00 (m, 2H), 1.6 (s, 6H); MS (APCI) *m/z* 196 ([M + H]⁺, 100%); Anal. Calc. For C₁₀H₁₀FNO₂: C, 61.53, H, 5.16, N, 7.18. Found: C, 61.27, H, 5.37, N, 7.02.

8-Fluoro-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid was prepared from 6-bromo-8-Fluoro-4,4-dimethyl-dihydro-benzo[d][1,3]oxazin-2-one using the procedure of Example 4.

3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile was prepared, from 8-fluoro-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 5-bromo-3-fluorobenzonitrile according to the procedure of example 5, as a white solid: mp 256-257 °C; ¹H-NMR (DMSO-d₆) δ 10.5 (s, 1H), 8.20 (bs, 1H), 8.06 (dt, 1H, *J* = 10.48, 2.16 Hz), 7.85-7.82 (m, 1H), 7.77 (dd, 1H, *J* = 11.89, 1.81 Hz), 7.63 (s, 1H), 1.7 (s, 6H); MS (EI) *m/z* 314([M]⁺, 60%).

The title compound was prepared, according to the procedure of Example 16 using 3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile, as a yellow solid: ¹H-NMR (CDCl₃) δ 8.91 (s, 1H), 7.61 (d, 1H), 7.47 (dt, 1H, *J* = 9.25, 2.0 Hz), 7.39 (m, 1H), 7.33-7.29 (m, 1H), 7.13 (s, 1H), 1.8 (s, 6H).

EXAMPLE 58

3-(1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)benzonitrile

5 3-(1,2-Dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-
benzonitrile was prepared, according to Procedure B from spiro-(4, 1'-cyclohexane-
1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 3-bromobenzonitrile, as
a tan powder: mp 245-247 °C; ¹H-NMR(DMSO-d₆) δ 10.31 (s, 1H), 8.21 (s, 1H),
8.02 (d, 1H, *J* = 8.0 Hz), 7.78 (d, 1H, *J* = 7.7 Hz), 7.68-7.61 (m, 3H), 6.97 (d, 1H, *J* =
10 8.2 Hz), 1.98-1.96 (m, 4H), 1.75-1.64 (m, 5H), 1.40-1.32 (m, 1H); MS (EI) *m/z*
318[M⁺]; Anal. Calc. For C₂₀H₁₈N₂O₂·1/2 H₂O: C 73.38; H, 5.85; N, 8.56. Found: C,
73.86; H, 5.81; N, 8.22.

The title compound was prepared, according to the procedure of Example 16
starting with 3-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-
15 yl)benzonitrile, as a white solid: mp 222-224°C; ¹H-NMR (CDCl₃) δ 9.08 (s, 1H),
7.86-7.81 (m, 1H), 7.77(dt, 1H, *J* = 7.79, 1.35 Hz), 7.67-7.64 (m, 1H), 7.58 (d, 1H, *J*
= 7.77 Hz), 7.48 (dd, 1H, *J* = 8.2, 1.93 Hz), 7.35 (d, 1H, *J* = 1.78 Hz), 6.91 (d, 1H, *J*
= 8.2 Hz), 2.30-2.26 (m, 2H), 2.07-1.98 (m, 2H), 1.90-1.70 (m, 4H), 1.39-1.24 (m,
2H); MS (ES) *m/z* 333 ([M-H]).

20

EXAMPLE 59

5-(1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-4-methyl-2-thiophenecarbonitrile

5-(1, 2-Dihydro-2-oxospiro[4H-3, 1-benzoxazine-4,1-cyclohexan]-6-yl)-4-
25 methyl-2-thiophenecarbonitrile was prepared, according to Procedure B from spiro-(4,
1'-cyclohexane-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 2-bromo-
3-methyl-5-cyanothiophene, as a white powder: mp 200-203 °C; ¹H-NMR (DMSO-d₆)
δ 10.4 (s, 1H), 7.85 (s, 1H), 7.43-7.40 (m, 2H), 7.0 (d, 1H, *J* = 8.8 Hz), 2.27 (s, 3 H),
2.00-1.62 (m, 9H), 1.42-1.23 (m, 1H); MS(EI) *m/z* 338 (M⁺); Anal. Calc. For
30 C₁₉H₁₈N₂O₂S: C, 67.43; H, 5.36, N, 8.28. Found: C, 67.12; H, 5.45; N, 8.05.

The title compound was prepared, according to the procedure for Example 16 starting with 5-(1,2-Dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-4-methyl-2-thiophenecarbonitrile, as a yellow solid: mp 199-201°C; ¹H-NMR (CDCl₃) δ 8.92 (s, 1H), 7.5 (s, 1H), 7.36 (dd, 1H, *J* = 8.17, 1.9 Hz), 7.23 (d, 1H, *J* = 1.7 Hz), 6.87 (d, 1H, *J* = 8.18 Hz), 2.3 (s, 3H), 2.05-1.70 (m, 7H), 1.36-1.25 (m, 3H); MS (ES) *m/z* 353 ([M-H]).

EXAMPLE 60

5-(1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-2-thiophenecarbonitrile

5-(1, 2-Dihydro-2-oxospiro[4H-3, 1-benzoxazine-4,1-cyclohexan]-6-yl)-2-thiophenecarbonitrile was prepared, according to Procedure B from spiro-(4, 1'-cyclohexane-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 2-bromo-5-cyanothiophene, as a tan powder: mp 243-245 °C; ¹H-NMR (DMSO-*d*₆) δ 10.41 (s, 1H), 7.98-7.97 (d, 1H, *J* = 3.9 Hz), 7.67-7.60 (m, 3H), 6.97-6.94 (d, 1H, *J* = 8.3 Hz), 1.98-1.92 (m, 4H), 1.74-1.64 (m, 5H), 1.45-1.21 (m, 1H); MS (EI) *m/z* 324 (M⁺). Anal. Calc. For C₁₈H₁₆N₂O₂S 1/2 H₂O: C, 65.08; H, 5.04; N, 8.18. Found: C, 64.84; H, 5.09; N, 8.40.

The title compound was prepared, according to the procedure for Example 16 starting with 5-(1,2-Dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl)-2-thiophenecarbonitrile, as a yellow solid: mp 232-233 °C; ¹H-NMR (CDCl₃) δ 8.90 (s, 1H), 7.6 (d, 1H, *J* = 3.93 Hz), 7.36 (d, 1H, *J* = 1.8 Hz), 7.24-7.20 (m, 1H), 6.85 (d, 1H, *J* = 8.25 Hz), 2.28-2.23 (m, 2H), 2.11-1.96 (m, 2H), 1.90-1.70 (m, 5H), 1.38-1.33 (m, 2H); MS (ES) *m/z* 339 ([M-H]).

EXAMPLE 61

6-(3-Chloro-4-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione

6-(3-Chloro-4-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared, from 6-bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one and 1-bromo-3-chloro-4-fluorobenzene according to Procedure A, as a white solid:

mp 211-212 °C; ¹H-NMR (DMSO-d₆) δ 10.4 (s, 1H), 7.92 (dd, 1H, *J* = 7.13, 2.19 Hz), 7.71-7.66 (m, 1H), 7.60-7.57 (m, 2H), 7.49 (t, 1H, *J* = 8.95 Hz), 6.96 (d, 1H, *J* = 8.01 Hz), 1.67 (s, 6H); MS (EI) *m/z* 305 ([M + H]⁺, 20%); Anal. Calc. For C₁₆H₁₃ClFNO₂: C, 62.86, H, 4.29, N, 4.58. Found: C, 62.52, H, 4.45, N, 4.42.

- 5 The title compound was prepared, according to the procedure for Example 16 starting with 6-(3-Chloro-4-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, as a white solid: mp 196-197 °C; ¹H-NMR (CDCl₃) δ 9.29 (s, 1H), 7.55 (dd, 1H, *J* = 6.89, 2.28 Hz), 7.45 (dd, 1H, *J* = 8.21, 1.91 Hz), 7.41-7.27 (m, 1H), 7.28-7.27 (m, 1H), 7.22 (t, 1H, *J* = 8.66 Hz), 6.92 (d, 1H, *J* = 8.22 Hz), 1.81
10 (s, 6H); MS (ES) *m/z* 320 ([M-H]⁻).

EXAMPLE 62

- 15 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-propylthiophene-2-carbonitrile

- 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-*n*-propylthiophene-2-carbonitrile was prepared according to Procedure B from spiro-(4, 1'-cyclohexane-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 2-bromo-3-*n*-
20 propyl-5-thiophenecarbonitrile. White crystals: mp 160-162 °C; IR (KBr) 2220 cm⁻¹; ¹H-NMR (DMSO-d₆) δ 10.47 (s, 1H), 7.93 (s, 1H), 7.38-7.36 (m, 2H), 7.01 (d, 1H, *J* = 8.7 Hz), 2.59-2.48 (m, 2H), 1.64-1.51 (m, 2H), 0.85 (t, 3H, *J* = 7.3 Hz). MS(-ESI) *m/z* [M-H]⁻ 325; Anal. Calc. For C₁₈H₁₈N₂O₂S·3/4H₂O: C, 63.60; H, 5.78, N, 8.24. Found: C, 63.48; H, 5.59; N, 8.04.

- 25 The title compound was prepared according to the procedure for Example 16 starting with 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-propyl-thiophene-2-carbonitrile. A yellow solid: mp 174-175°C; ¹H-NMR (CDCl₃) δ
9.43 (s, 1H), 7.49 (s, 1H), 7.35 (dd, 1H, *J* = 8.17, 1.8 Hz), 7.19 (d, 1H, *J* = 1.62 Hz),
6.95 (d, 1H, *J* = 8.18 Hz), 2.56 (t, 2H, *J* = 7.53 Hz), 1.79 (s, 6H), 1.60 (m, 2H, *J* =
30 7.56 Hz), 0.92 (t, 3H, *J* = 7.3 Hz); MS (ES) *m/z* 341 ([M-H]⁺).

EXAMPLE 63

4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile

4-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-furan-2-carbonitrile was prepared from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid and 4-bromo-2-furancarbonitrile according to Procedure B. Off-white solid: mp 255-256 °C. ¹H-NMR (DMSO-d₆) δ 10.32 (s, 1H, D₂O exchangeable), 8.57 (s, 1H), 8.15 (s, 1H), 7.61 (s, 1H), 7.55 (dd, 1H, J = 8.3, 1.5 Hz), 6.92 (d, 1H, J = 8.2 Hz), 1.65 (s, 6H); MS (ESI) m/z 269 (M+H, 72%). Anal. Calc. For C₁₅H₁₂N₂O₃: C, 67.16, H, 4.51, N, 10.44. Found: C, 67.14, H, 4.59, N, 10.07.

The title compound was prepared according to the procedure for Example 16 starting with 4-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-furan-2-carbonitrile. An off-white solid: mp 214-216°C; ¹H-NMR (CDCl₃) δ 8.93 (s, 1H), 7.83 (s, 1H), 7.39 (dd, 1H, J = 8.2, 1.87 Hz), 7.35 (s, 1H), 7.22-7.21 (m, 1H), 6.86 (d, 1H, J = 8.2 Hz), 1.79 (s, 6H); MS (ES) m/z 283 ([M-H]⁺).

EXAMPLE 64

4-Butyl-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile

5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-4-n-butylthiophene-2-carbonitrile was prepared according to Procedure B from spiro-(4, 1'-cyclohexane-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl) boronic acid and 2-bromo-3-n-butyl-5-thiophenecarbonitrile. White crystals: mp 167-168 °C; ¹H-NMR (DMSO-d₆) δ 10.46 (s, 1H), 7.93 (s, 1H), 7.38-7.36 (m, 2H), 7.01 (d, 1H, J = 8.7 Hz), 2.59 (t, 2H, J = 8.1 Hz), 1.63 (s, 6H), 1.58-1.51 (m, 2H), 1.48-1.17 (m, 2H), 0.82 (t, 3H, J = 7.4 Hz). MS(-ESI) m/z [M-H]⁺ 339. Anal. Calc. For C₁₉H₂₀N₂O₂S·1/4 H₂O: C, 66.16; H, 5.99; N, 8.12. Found: C, 66.33; H, 5.92; N, 7.85.

The title compound was prepared according to the procedure for Example 16 starting with 4-Butyl-5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-2-carbonitrile. A yellow solid: mp 174-175°C; ¹H-NMR (CDCl₃) δ 9.58 (s, 1H), 7.50 (s, 1H), 7.35 (dd, 1H, J = 8.19, 1.84 Hz), 7.19 (d, 1H, J = 1.7 Hz), 6.96

(d, 1H, $J = 8.18$ Hz), 2.58 (t, 2H, $J = 7.61$ Hz), 1.80 (s, 6H), 1.61- 1.54 (m, 2H), 1.35-1.25 (m, 2H), 0.88 (t, 3H, $J = 7.29$ Hz); MS (ES) m/z 355 ([M-H]⁺).

EXAMPLE 65

5 **6-(3-Bromophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione**

6-(3-Bromo-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one was prepared from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 1,3-dibromobenzene according to procedure B. A white solid: mp 174-175 °C; ¹H-NMR (DMSO-d₆) δ 10.35 (s, 1H), 7.88 (bs, 1H), 7.68 (d, 1H, $J = 7.5$ Hz), 7.6-
10 7.51 (m, 3H), 7.4 (t, 1H, $J = 7.5$ Hz), 6.97 (d, 1H, $J = 8.57$ Hz), 1.64 (s, 6H); MS (EI) m/z 331([M⁺], 60%), 333([M⁺], 60%); Anal. Calc. For C₁₆H₁₄BrNO₂: C, 57.85, H, 4.25, N, 4.22. Found: C, 57.7, H, 4.36, N, 4.09.

A mixture of 6-(3-bromo-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (3 g, 9.04 mmol) and Lawesson's Reagent (1.83 g, 4.51
15 mmol) in toluene (30 mL) was heated to 110°C for 24 hours. The reaction was cooled, the toluene removed *in vacuo* and the residue purified via flash chromatography (silica gel, 20% ethyl acetate/hexane) to give 6-(3-bromophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione (1.93 g, 61%) as a yellow solid: mp 191-193°C; ¹H-NMR (DMSO-d₆) δ 12.3 (s, 1H), 7.92 (s, 1H), 7.72-7.65 (m, 3H),
20 7.57-7.54 (m, 1H); 7.45-7.39 (m, 1H), 7.14-7.11 (m, 1H), 1.7 (s, 6H); MS (ES) m/z 347 ([M-H]⁺, 100%); Anal. Calc. For C₁₆H₁₄BrNOS: C, 55.18, H, 4.05, N, 4.02 Found: C, 55.17, H, 3.93, N, 3.97

EXAMPLE 66

25 **2-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-3-carbonitrile**

2-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-3-carbonitrile was prepared according to procedure B from (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxin-6-yl)boronic acid and 2-bromo-3-thiophenecarbonitrile. An
30 off-white solid: mp 200-202 °C; ¹H-NMR (DMSO-d₆) δ 10.49 (s, 1H), 7.75(m,


1H), 7.63(d, 1H, $J = 2.2$ Hz), 7.59 (m, 1H), 7.50 (m, 1H), 7.02 (d, 1H, $J = 8.1$ Hz), 1.63(s, 6H); MS(-ESI) m/z 283 (M-H)⁻.

The title compound was prepared according to the procedure for Example 16 starting with 2-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-
5 thiophene-3-carbonitrile. A yellow solid: mp 194-195°C; ¹H-NMR (CDCl₃) δ 9.56 (s, 1H), 7.67-7.62 (m, 2H), 7.35 (d, 1H, $J = 5.39$ Hz), 7.30 (d, 1H, $J = 5.33$ Hz), 6.98 (d, 1H, $J = 8.18$ Hz), 1.80 (s, 6H); MS (ES) m/z 299 ([M-H]⁻).

All publications cited in this specification are incorporated herein by
10 reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.

What is Claimed:

1. A compound of the formula:



wherein:

R_1 and R_2 are independent substituents selected from the group of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_2 to C_6 alkenyl, substituted C_2 to C_6 alkenyl, C_2 to C_6 alkynyl, substituted C_2 to C_6 alkynyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , or $NR^B COR^A$;

or R^1 and R^2 are fused to form a spirocyclic ring selected from a), b) or c), below, each spirocyclic ring being optionally substituted by from 1 to 3 substituents selected from H or C_1 - C_3 alkyl:

a) a 3 to 8 membered spirocyclic alkyl ring, preferably a 3 to 6 membered spirocyclic alkyl ring; or

b) a 3 to 8 membered spirocyclic alkenyl ring, preferably a 3 to 6 membered spirocyclic alkenyl ring; or

c) a 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocyclic ring containing one to three heteroatoms;

R^A is selected from H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, amino, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^B is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;


R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_1 to C_6 alkenyl, alkynyl, or substituted alkynyl, or COR^C ;

R^C is selected from H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^4 is selected from H, halogen, CN, NO_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, or substituted C_1 to C_6 aminoalkyl;

R^5 is selected from groups a), b), or c) below:

a) R^5 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below:



X is selected from the group including halogen, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkoxy, substituted C_1 to C_3 thioalkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D , $OCOR^D$, or $NR^E COR^D$;

R^D is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independent substituents selected from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkoxy;
or


b) R^5 is a five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, S(O), S(O)₂ or NR⁶ and containing one or two independent substituents from the group of H, halogen, CN, NO_2 and C_1 to C_3 alkyl, C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, COR^F, or NR^GCOR^F;

R^F is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^G is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

R^6 is H, or C_1 to C_3 alkyl; or

c) or R^5 is a six membered ring with the structure:



wherein:

X^1 is N or CX²,

X^2 is halogen, CN, or NO_2 .


Q^1 is S, NR^7 , or CR^8R^9 ;

R_7 is selected from the group of CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, or substituted heterocyclic, SO_2CF_3 , OR^{11} or $NR^{11}R^{12}$;


R^8 and R^9 are independent substituents selected from the group of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN, or CO_2R^{10} ;

R^{10} is C_1 to C_3 alkyl;

or CR^8R^9 comprise a six membered ring as shown by the structure below:




Q^2 is selected from the moieties:



R^{11} , R^{12} and R^{13} are independently selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 having the structure:



wherein:

R^1 is H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , or $NR^B COR^A$;

R^2 is H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_2 to C_6 alkenyl, substituted C_2 to C_6 alkenyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , or $NR^B COR^A$;

or R^1 and R^2 are fused to form a spirocyclic ring selected from a), b) or c), below, each spirocyclic ring being optionally substituted by from 1 to 3 substituents selected from H or C_1 - C_3 alkyl:

a) a 3 to 8 membered spirocyclic alkyl ring, preferably a 3 to 6 membered spirocyclic alkyl ring; or

b) a 3 to 8 membered spirocyclic alkenyl ring, preferably a 3 to 6 membered spirocyclic alkenyl ring; or

c) a 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocyclic ring containing one to three heteroatoms;

R^A is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;


R^B is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_1 to C_6 alkenyl, alkynyl, or substituted alkynyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, substituted C_1 to C_4 alkyl, aryl, substituted aryl, C_1 to C_4 alkoxy, substituted C_1 to C_4 alkoxy, C_1 to C_4 aminoalkyl, or substituted C_1 to C_4 aminoalkyl;

R^4 is H, halogen, CN, NO_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, or substituted C_1 to C_6 aminoalkyl;

R^5 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below,



X is taken from the group including halogen, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkoxy, substituted C_1 to C_3 thioalkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D , $OCOR^D$, or $NR^E COR^D$;

R^D is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independent substituents taken from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkoxy;

or

R^5 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO_2 or NR^6 and containing one or two independent substituents from the group including H, halogen, CN, NO_2 and C_1 to C_3 alkyl, C_1 to C_3 alkoxy,

R^6 is H, or C_1 to C_3 alkyl,


Q^1 is S, NR^7 , CR^8R^9 ,

R_7 is selected from CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^8 and R^9 are independent substituents from the group including H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN , CO_2R^{10} ;


R^{10} is C_1 to C_3 alkyl;

or CR^8R^9 comprise a six membered ring as shown by the structure below



or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 2 having the structure:



R^1 and R^2 are independently selected from the group of C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 3 to 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy;

R^4 is H, halogen, NO_2 , C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

X is selected from the group of halogen, CN, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C_1 to C_3 thioalkoxy;

Y is a substituent selected from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_4 alkyl, or C_1 to C_3 thioalkoxy;


Q^1 is S, NR^7 , or CR^8R^9 ;

R^7 is selected from the group of CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^8 and R^9 are independent substituents selected from the group of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN or CO_2R^{10} ;


R^{10} is C_1 to C_3 alkyl;

or CR^8R^9 comprises a six membered ring as shown by the structure below



or a pharmaceutically acceptable salts thereof.

4. A compound of Claim 2 having the structure:



R^1 and R^2 are independently selected from the group of C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 3 to 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy;

R^4 is H, halogen, NO_2 , C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

X is selected from the group of halogen, CN, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C_1 to C_3 thioalkoxy;

Y is a substituent selected from the group of H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_4 alkyl, or C_1 to C_3 thioalkoxy;

U is O, S, or NR^6 ;

R^6 is H, or C_1 to C_3 alkyl, or C_1 to C_4 CO_2 alkyl;


Q is S, NR^7 , or CR^8R^9 ;

R^7 is selected from the group of CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^8 and R^9 are independent substituents selected from the group of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN or CO_2R^{10} ;


R^{10} is C_1 to C_3 alkyl;

or CR^8R^9 together comprises a six membered ring of the structure:



or a pharmaceutically acceptable salts thereof

5. A compound of Claim 2 having the formula:



wherein:

R¹ and R² are independently selected from the group of C₁ to C₃ alkyl or substituted C₁ to C₃ alkyl, or R¹ and R² are fused to form a 3 to 6 membered spirocyclic alkyl ring;

R³ is H, OH, NH₂, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, or COR^C;

R^C is H, C₁ to C₄ alkyl, or C₁ to C₄ alkoxy;

R⁴ is H, halogen, NO₂, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

X¹ is N or CX²;

X² is halogen, CN, or NO₂; and

Q is S, NR⁷, or CR⁸R⁹;

or a pharmaceutically acceptable salt thereof.

6. A compound of Claim 1 which is 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione or a pharmaceutically acceptable salt thereof.

7. A compound of Claim 1 which is 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-thiophene-2-carbonitrile or a pharmaceutically acceptable salt thereof.

8. A compound of Claim 1 which is 6-Bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione or a pharmaceutically acceptable salt thereof.

9. A compound of Claim 1 which is 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile or a pharmaceutically acceptable salt thereof.

10. A compound of Claim 1 which is 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-benzonitrile or a pharmaceutically acceptable salt thereof.

11. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/11749

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D265/18 C07D413/04 A61K31/536 A61P15/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 14436 A (DU PONT MERCK PHARMA) 9 April 1998 (1998-04-09) cited in the application pages 132-134; pages 148-150; claims ---	1-4, 12
X	EP 0 510 235 A (DONG A PHARM CO LTD) 28 October 1992 (1992-10-28) claims ---	1-4, 12
A	WO 95 20389 A (MERCK & CO INC) 3 August 1995 (1995-08-03) cited in the application claims --- -/--	1, 12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 September 2000

Date of mailing of the international search report

13/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo rd,
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/11749

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 96 19458 A (LIGAND PHARM INC) 27 June 1996 (1996-06-27) claims & US 5 688 810 A 18 November 1997 (1997-11-18) cited in the application -----</p>	1, 12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/11749

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9814436	A	09-04-1998	AU 4802797 A EP 0929533 A ZA 9708759 A	24-04-1998 21-07-1999 30-03-1999
EP 0510235	A	28-10-1992	NONE	
WO 9520389	A	03-08-1995	AU 1694295 A US 5663169 A US 5665720 A US 5519021 A US 5811423 A	15-08-1995 02-09-1997 09-09-1997 21-05-1996 22-09-1998
WO 9619458	A	27-06-1996	US 5688810 A US 5688808 A US 5693647 A US 5696127 A US 5693646 A US 5696130 A US 5696133 A AU 717251 B AU 4597796 A BR 9510486 A CA 2208347 A CN 1175247 A CZ 9701761 A EP 0800519 A HU 78117 A JP 10510840 T NO 972591 A US 6093821 A US 5994544 A	18-11-1997 18-11-1997 02-12-1997 09-12-1997 02-12-1997 09-12-1997 09-12-1997 23-03-2000 10-07-1996 02-06-1998 27-06-1996 04-03-1998 16-09-1998 15-10-1997 29-11-1999 20-10-1998 14-08-1997 25-07-2000 30-11-1999